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Oesophageal squamous cell carcinoma (OSCC) is the 8th most common cancer worldwide 
with high incidence in areas that include China, Iran and South Africa.	  The current treatment 
available for OSCC does not significantly enhance patient survival. A better understanding of 
proliferative and survival pathways activated in OSCC could allow identification of more 
specific therapeutic targets, potentially improving management of OSCC. Cell surface 
receptors are known to play important roles in relaying signals from the extracellular 
environment. They are often overexpressed in cancer cells, thus making them interesting drug 
targets for cancer therapy. The epidermal growth factor receptor (EGFR), the type 1 insulin-
like growth factor receptor (IGF-1R) and the chemokine CXC receptor 2 (CXCR2) are 
examples of receptors commonly overexpressed in OSCC. The aim of this study was to 
determine the role of EGFR, IGF-1R and CXCR2 in proliferation and survival of OSCC 
cells. 
Here we show that in OSCC cell lines, stimulation with EGF resulted in rapid 
phosphorylation of IGF-1R which was dependent on EGFR kinase activity. IGF-1R/Akt 
activity suppressed EGFR and ERK1/2 activity when cells were treated with IGF-1. This 
repression was relieved when IGF-1R was knocked down, as cells displayed elevated pEGFR 
and pERK1/2 levels. Ablation of EGFR activity by antagonist or siRNA reduced proliferation 
of WHCO1 and WHCO6 cells by 30-40% suggesting a role for EGFR in proliferation. 
Furthermore, co-targeting of EGFR and IGF-1R, but not IGF-1R combined with Cisplatin or 














In a previous study we have shown that the chemokine CXC receptor 2 (CXCR2) and its 
ligands Groα and Groβ are upregulated in OSCC patient tissue compared to normal adjacent 
tissue. Inhibition of CXCR2 with neutralising antibody or shRNA specific to CXCR2 had no 
effect on cell proliferation or survival. However, treatment of OSCC cells WHCO1 and 
WHCO6 with CXCR2 antagonist SB225002 blocked proliferation with an IC50 of 2.5 µM, 
while normal fibroblast cell DMB and WI38 were unaffected. Cell proliferation was 
significantly inhibited in the presence of 2 µM SB225002 and a G2/M arrest was observed 
after 8 hrs of incubation with drug. SB225002 induced DNA damage and apoptosis in 
WHCO1 and WHCO6 OSCC cells at the 24 and 48 hr time points. WHCO1 and WHCO6 
CXCR2 knockdown cells were less sensitive to SB225002 as no effect on cell cycle and 
proliferation was observed in the presence SB225002 compared to control cells. Taken 
together these data suggests that CXCR2 is important in mediating SB225002-induced 
apoptosis of OSCC cells which over-express this receptor while CXCR2 negative cells are 
not affected by SB225002. 
Our data suggest that EGFR, IGF-1R and CXCR2 are novel potential therapeutic targets for 
OSCC as either co-targeting of EGFR and IGF-1R or targeting of CXCR2 results in apoptosis 















1.1 Cancer  
Despite references to cancer in texts dating as far back as 3000 BC, our knowledge of this 
disease has not yet lead to its eradication – in fact, it is still one of the leading causes of 
morbidity and death worldwide (Hajdu 2011). It is estimated that one quarter of people living 
in the developed world will die as a result of cancer (Hamilton, 2010). Better diagnostic 
markers and more specific treatment targets need to be identified for improving patient 
survival. This explains the huge amount of funding and resources poured into research to 
better understand cancer as a disease process.  As a direct result of this relentless effort, 
researchers were able to identify distinct differences between normal and cancer cells that 
could potentially be exploited to identify and target cancer cells. These multiple and complex 
differences were succinctly summarized by Hanahan and Weinberg (2000) as the six 
hallmarks of cancer, including the evasion of apoptosis, uncontrolled proliferation and 
angiogenesis with the 7th proposed hallmark linking inflammation with cancer (Cavallo et al. 
2011). Major differences separating cancer cells from normal cells include tumour specific 
antigens, tumour specific oncogenes e.g. BCR-ABL and loss of tumour suppressor-gene 
function (Basilion et al. 1999).  Selective targeting of tumour specific oncogenes like BCR-
ABL in chronic myologenous leukemic patients and HER2 in breast cancer patients results in 
improved survival (Cao et al. 2008). Sadly, not all cancers share the same ‘Achilles’ heel’ 
and rigorous research searching for tumour specific oncogenes is still on-going. Esophageal 













1.2 Oesophageal Cancer  
 
Oesophageal cancer (OC) is the 8th most common cancer worldwide, the sixth leading cause 
of cancer related deaths with an overall 5 year survival around 10% (Enzinger & Mayer 
2003; Pickens & Orringer 2003; Ekman et al. 2007; Stoner et al. 2007; Mitry et al. 2008). 
Oesophageal cancer presents predominantly as two histological subtypes namely: squamous 
cell carcinoma (SCC) occurring in the middle and lower third of the oesophagus and 
adenocarcinoma (AC) which is found in the distal part of the oesophagus. In developed 
regions like Western Europe and North America incidence rates for oesophageal squamous 
cell carcinoma (OSCC) are as low as 3-5/100 000 while in certain regions including Iraq, 
parts of Europe, Southern Africa and Iran the incidence is between 8-13/100 000 (Layke & 
Lopez, 2006; Pickens & Orringer, 2003; Zhou et al. 2006). Incidence rates in parts of China 
have been found to exceed 100 per 100 000 (Enzinger & Mayer 2003; Stoner et al. 2007; 
Guo et al. 2008; Zheng et al. 2009). According to statistics released by the International 
Agency for Research on Cancer (IARC) (www-dep.iarc.fr), high death rates were observed in 
regions with high incidence rates for OSCC in 2008 (Fig. 1) (Bosetti et al. 2008). While 
OSCC is more prevalent in developing countries than adenocarcinoma, the reverse is true in 
developed countries. Barrets Oesophagus, (in which stratified squamous epithelial cells are 
replaced with columnar epithelial cells), is considered a premalignant form of AC since these 
patients have an increased risk for developing AC (Enzinger & Mayer 2003). Recent 
evidence suggests that obesity, acid reflux and Barrets oesophagus are risk factors for AC in 
first world nations (Tew et al. 2005; Layke & Lopez 2006).   
Treatment for OSCC includes surgery, radiation therapy and chemotherapy which are 
sometimes used in combination. Surgery is only approved and advised if the cancer is 












have shown that patients diagnosed with early stage OSCC who have undergone surgery have 
5 year survival rates between 15-24%, highlighting the poor prognosis for this disease 
(Enzinger & Mayer 2003). Radiotherapy can yield similar survival rates, although it is less 

















A major contributing factor to poor patient survival is the poor detection of early stage OSCC 
– consequently, most patients (greater than 50%) present with advanced stage III or IV 
OSCC, in which case the tumour is unresectable or has already metastasised (Tew et al. 
2005; Guo et al. 2008). When patients with advanced disease are treated with 
chemotherapeutic agents such as cisplatin and 5-fluorouracil, 50-60% show initial response 
Figure 1: World-wide OSCC incidence rates  
GLOBOCAN world-wide incidence rates for OSCC per 100,000 individuals in 2008. From GLOBOCAN 2008, 
International Agency for Research on Cancer, Lyon, France, 2004. (www-dep.iarc.fr).The figure legend depicts 
number of OSCC cases per 100,000 individuals. OSCC incidence is high in underdeveloped countries along the 
Eastern seaboard of Africa while less common in developed countries like America.  












for the first few months. However resistance to therapy soon develops and patients often 
succumb within a year. Although strategies to improve survival, in which radiotherapy and 
chemotherapy or pre/postoperative radio/chemotherapy are combined, the 5 year survival rate 
for OSCC remains unchanged, despite short term benefits (Layke & Lopez 2006). New 
therapeutic interventions and prognostic markers for the management of OSCC are highly 
sought after. Although it is recognised that certain factors like alcohol consumption, smoking, 
certain genetic alterations and chemical insults contribute to the development of OSCC, there 
is still a poor understanding of the molecular pathways responsible for the development and 
maintenance of oesophageal cancer. Preliminary evidence obtained in our laboratory 
indicated that a suite of genes including EGFR, IGF-1R and CXCR2 may be implicated in the 
maintenance of the cancer phenotype in OSCC (Whibley et al. 2005; Wang et al. 2006; 
Whibley et al. 2007; Wang et al. 2009). The signalling pathways reviewed below are 
frequently dysregulated in many cancers and could provide clues to the processes that operate 
in oesophageal cancer. This review will focus on those genes and their associated signalling 





















1.3 Epidermal Growth Factor Receptor (EGFR)  
 
The epidermal growth factor receptor (EGFR) belongs to a four member family of receptors 
that include EGFR/ErbB1, Her2/Neu/ErbB2, Her3/ErbB3 and Her4/ErbB4 (Fig. 2) 
(Normanno et al. 2006; Bianco et al. 2007; Wei et al. 2007). The EGFR gene, located in the 
region of 7p13-q22, codes for a 170kDa protein that consists of an extracellular domain for 
ligand binding; a transmembrane domain for anchorage and a cytoplasmic domain containing 
an ATP binding kinase domain (Bianco et al. 2007; Wei et al. 2007). After translation of the 
EGFR mRNA the alpha and beta subunits dimerize with each other in a 2:2 complex 
containing two alpha and two beta subunits. The ErbB family receptors are highly 
homologous to such an extent that homo/hetero – dimerization occur between these receptors. 
Her2 has a constitutively active conformation, and there is no known ligand for this receptor.  
The conformational state of this protein, makes it the preferred dimerization partner for other 
ERB family members because its dimerization loop is always exposed (Wang et al. 2006). 
Her2 as the preferred dimerization partner of EGFR increases receptor stability and targets 
the receptor for recycling where it can be reutilized. Activation of EGFR can either occur 
through direct or indirect interactions. Direct activation occurs when ligands bind the 
extracellular ligand binding domain of the receptor. Ligands recognized by EGFR include: 
epidermal growth factor (EGF), transforming growth factor alpha (TGF-α), amphiregulin 
(AR), heparin-binding EGF-like growth factor (HB-EGF) and betacellulin (BTC) (Fig. 2) 
(Normanno et al. 2006). Indirect activation includes transactivation by other receptors like G 
protein coupled receptors (GPCR) or the insulin growth factor 1 receptor (IGF-1R) and 













Figure 2: HER family structure and ligand identity   
The HER family of receptors are divided into three domains: an extracellular ligand-binding domain with two 
cysteine-rich regions (CR1 and CR2), a transmembrane domain and an intracellular kinase domain. All receptors 
are capable of homo/heterodimerization with each other upon binding ligand. All HER receptors, with the 
exception of HER2, have known ligands. (EGF – epidermal growth factor, EGFR – epidermal growth factor 
receptor, HER – human epidermal receptor, X – kinase inactive/dead, HB-EGF heparin-binding epidermal 
growth factor, NRG – neuregulin and TGFα – transforming growth factor alpha).  From Rowinsky (2004). 
   
Upon activation of the EGF receptor, homo/heterodimerization followed by 
autophosphorylation of tyrosine and serine residues occurs. Signalling complexes and adaptor 
proteins are recruited to the membrane and associate with activated EGFR (Fig. 3). 
Activation of the Ras/Raf/MAPK, JAK/STAT, PI3K-AKT and PLCy pathways then give rise 














Reports have shown compelling evidence that EGFR exerts its effects mostly through the 
Ras/Raf/MEK/ERK1/2 pathway as this pathway is more strongly activated by EGFR than the 
PI3K-AKT and other pathways (Cao et al. 2008; Hu et al. 2008; Villanueva et al. 2010). The 
Ras/Raf/MEK/ERK1/2 pathway activates more than 140 target proteins, with its best known 
role being activation of proliferation (Khavari & Rinn, 2007). Activation of Ras leads to 
increased proliferation and inhibits differentiation of keratinocytes (Kern et al. 2011). Animal 
models containing constitutively activated Ras or MEK display hyperplasia in the epidermis 
(Kern et al., 2011). Redundancies exist in this pathway since Ras and Raf have many 
isoforms which ensures activation of the Ras/Raf/MEK/ERK1/2 pathway. Ras isoforms 
include Ha-Ras, N-Ras and Ki-Ras (McCubrey et al. 2007).  
Ras is a GTPase and can be activated by receptor tyrosine kinases like EGFR. Once EGFR is 
activated, adaptor proteins Grb2 and SOS bind EGFR and recruit Ras. Ras is then activated 
by exchanging GDP for GTP, leading to a cascade of downstream phosphorylation events, 
including the Raf/MEK/ERK1/2 and PI3K pathways as shown in Fig. 3 (Normanno et al. 
2006; Khavari & Rinn 2007; McCubrey et al. 2007).  Consistent with the importance of the 
Ras/Raf/MEK/ERK1/2 pathway in proliferation, it is not surprising that 25-30% of all human 
tumours contain activating Ras mutations (Katz et al. 2007; Khavari & Rinn 2007). Ras 
activity is also much higher in squamous cell carcinomas compared to normal cells despite 
the absence of mutations suggesting the presence of multiple pathways that could lead to the 
activation of this critical signalling pathway (Khavari & Rinn 2007). Three Raf isoforms 
namely; Raf1 (C-Raf), A-Raf and B-Raf are all capable of activating MEK with different 
affinities (Boutros et al. 2008). B-Raf is the most commonly mutated Raf isoform and is 
mutated in as much as 50% of melanomas (Villanueva et al. 2010). Following Raf activation, 
MEK is phosphorylated, which in turn activates ERK1/2. Although unphosphorylated MEK 












disrupts MEK/ERK1/2 interactions (Boutros et al. 2008). Activated ERK1/2 translocates to 
the nucleus and activates transcription factors or directly phosphorylates proteins involved in 
cell migration, proliferation, differentiation or apoptosis. The Ras/Raf/MEK/ERK1/2 
pathway is also known to activate phosphorylation of pro-apoptotic proteins including Bad 
and Bim resulting in their degradation, while phosphorylation of anti-apoptotic proteins Mcl-
1 and BCL-2 by ERK1/2 stabilises these proteins (McCubrey et al. 2007). ERK1/2 
translocation to the nucleus results in stabilisation of the transcription factor c-Myc which 
facilitates transcription of cyclin D1 and Elk which in turn induces transcription of the c-fos 
gene.  These genes are all involved in regulating cell cycle progression (Fig. 3) (Katz et al. 
2007; Boutros et al. 2008). Furthermore, activation of AP-1 by ERK1/2 could lead to the 
transcription of matrix metalloproteases (MMPs) which are involved with extracellular 
remodelling and cell migration (Katz et al. 2007). Most receptor tyrosine kinases activate the 
Ras/Raf/MEK/ERK1/2 pathway because of the central role it plays in activating a multitude 































Figure 3: MAPK signalling 
Upon binding ligand RTKs like EGFR dimerize resulting in autophosphorylation. Adapter proteins Shc, Grb2 
and PI3K are recruited to the activated RTK and in turn become phosphorylated. These activated adapter 
proteins can then relay signals down the various MAPK pathways, by phosphorylating their substrates, resulting 
in activation of transcription factors which transcribe genes involved in cell cycle progression, survival and 
migration.   Adapted from Katz et al., 2007. 












1.3.1 EGFR as a target in cancer   
In many cancers the EGFR has been implicated as a major contributor to tumour aggression 
where it is often mutated, overexpressed or transactivated in cancer cells.  EGFR 
overexpression and mutations occur in many tumours including: oesophageal (92%), 
colorectal (72%), prostrate (65%) and lung (50%) cancers (Tew et al. 2005). Tumour 
aggressiveness, poor prognosis and survival also correlate with EGFR overexpression. This 
correlation between EGFR expression and patient survival has prompted huge investment 
into research in order to elucidate the structure of EGFR and develop inhibitors for this 
receptor. Monoclonal antibodies, like Cetuximab, targeting the extracellular domain of 
EGFR, and kinase inhibitors, like Erlotinib and Gefitinib (Iressa), targeting the ATP binding 
pocket of EGFR have subsequently been developed and approved for clinical evaluation for 
certain cancers. The first cancer in which EGFR targeted therapy was evaluated was in Non-
small Cell Lung Cancers (NSCLC) which showed overexpression of EGFR. However, only a 
subset of patients showed clinical response with either tumour regression or stable disease 
when EGFR was specifically targeted (Sharma et al. 2007; Yun et al. 2007). It was later 
discovered that NSCLC patients bearing mutant EGFR (kinase domain mutations L858R and 
G719S) were the responders. These EGFR kinase domain mutations have been shown to be 
critical in tumour proliferation and survival as these tumours rely on constitutively activated 
EGFR and its major downstream Ras/Raf/MEK/ERK1/2 pathway (Hynes & Schlange 2006; 
Yun et al. 2007). Erlotinib was approved in 2004 for treatment of locally advanced or 
metastatic NSCLC patients in which chemotherapy was not effective while Gefitinib is 
approved only for patients who have shown response to this inhibitor (Morgillo et al. 2007a). 
Interestingly, a difference in the proportion of clinical responders has been observed in 












NSCLC patients of Asian ethnicity treated with EGFR inhibitors show response rates of 30-
50% while only 10% of patients of West European or North American ethnicity show clinical 
response to EGFR therapy (Sharma et al. 2007). Further investigation revealed that most 
responders were non-smokers and that EGFR mutations were more frequent in the Asian 
population than the European population. Aside from NSCLC, EGFR inhibitors have also 
been approved for breast cancer, Head and Neck Squamous Cell Carcinoma and Colorectal 
cancer. However similar response rates are observed for these cancers as with NSCLC 
(Cohen et al. 2005; Ono & Kuwano 2006). EGFR mutations in these cancers are not the sole 
predictor of response to EGFR inhibitors, suggesting that other mechanisms also play a role 
in response. Because EGFR is commonly overexpressed in OSCC, it has been investigated as 
a potential target in this disease.  Gefitinib treatment in advanced OSCC patients only 
resulted in a 10% patient response rate consistent with reports of EGFR targeted therapy in 
other cancers (Ferry et al. 2007; Sudo et al. 2007). Many trials and studies have shown that 
inhibition of EGFR has only benefited a subset of patients even though EGFR is 



















1.4 Type-1 Insulin-like Growth Factor Receptor (IGF-1R) 
 
The insulin-like growth factor receptor (IGF-1R) is a receptor tyrosine kinase essential for 
cell growth, differentiation and survival. IGF-1R is encoded by a single copy gene located on 
chromosome 15q25-q26 which encodes a polypeptide chain of 1367 amino acids (Hopfner et 
al. 2006; Adachi et al. 2010). Other family members include the Insulin receptor, which has 
two isoforms namely Insulin receptor A (IR-A) and Insulin receptor B (IR-B), and the type 2 
Insulin-like growth factor receptor (IGF-2R) (Pandini et al. 2007). Both the IR and IGF-1R 
consist of two alpha extracellular ligand binding domain subunits and two beta subunit chains 
containing a juxtamembrane region embedded in the cell membrane, an intracellular 
cytoplasmic kinase domain and a carboxyl-terminal domain (Dupont et al. 2003). These two 
receptors are highly conserved with the greatest homology in the kinase domain (84%) 
(Dupont et al. 2003; García-Echeverría et al. 2004). Ligands for these 3 receptors include 
insulin (Ins), insulin growth factor 1 (IGF-1) and insulin growth factor 2 (IGF-2), each 
binding with different affinities to the respective receptors. IGF-1 and IGF-2 bind IGF-1R 
with an affinity 500-1000 fold higher than Ins (Hopfner et al. 2006). Hybrid receptors are 
capable of binding both Ins or IGF-1. Although the IGF-2R receptor is kinase deficient its 
known function is to sequester IGF-2 in order to dampen signalling by IRA and IGF-1R (Zha 
& Lackner 2010). The physiological role of IGF-1 is to activate cell growth and provide 
protective signals to enhance normal cell survival under stressful or growth factor deficient 
conditions. IGF-1 protects and assists normal cells in recovery after ischemia or traumatic 
brain injury (Kurmasheva & Houghton 2006). Secretion of Ins is tightly controlled as it is 
only required during periods of high blood glucose while IGF-1 production and secretion is 
under endocrine regulation by growth hormone (Hartog et al. 2007).  Although IGF-1 and Ins 












pancreas (Blakesley et al. 1996; Massoner et al. 2010; Zha & Lackner 2010). Furthermore 
insulin growth factor binding proteins (IGFBPs) also regulate the availability of IGFs since 
they bind IGF in the serum, protecting these ligands from degradation (Lee et al. 2002; 
Hartog et al. 2007).   
 
The major downstream signalling pathway of the IGF-1R system is phosphatidylinositol 3-
kinase (PI3K) - AKT (Hu et al. 2008). After binding ligand IGF-1R becomes 
autophosphorylated resulting in recruitment of insulin receptor substrate (IRS) and 
translocation of (PI3K) to the cell membrane (Fig. 4). In the process, phosphatidylinositol-
3,4-bisphosphate (PIP2) is converted to phosphatidylinositol-3,4,5-triphosphate (PIP3) (Fig. 
4). The presence of PIP3 attracts AKT to the plasma membrane leading to the activation of 
AKT by PDK1 (LoPiccolo et al. 2007). PTEN (phosphatase and tensin homologue deleted on 
chromosome ten), a lipid phosphatase which catalyses the conversion of PIP3 to PIP2, in 




















Figure 4: IGF-1R activation by ligands and downstream signalling 
IGF-1R recognizes and is activated by both IGF-1 and IGF-2, however, their availability is controlled by 
IGFBPs and IGF-2R that bind IGF-2. Once activated by ligand, IGF-1R homo/heterodimerizes resulting in 
autophosphorylation and activation of downstream signal molecules IRS and Shc. Binding and phosphorylation 
of IRS1/2 results in activation of phosphatidyl inositol 3’ kinase (PI3K). Consequently PIP2 is converted to PIP3 
resulting in the recruitment of AKT to the plasma membrane where it becomes activated. AKT is then capable of 
phosphorylating downstream targets mTORC1, GSK-3β and others which are involved in protein synthesis, 
glucose metabolism, proliferation and survival. Recruitment and activation of Shc results in activation of the 
Ras/MAPK pathway which also stimulates cell proliferation. Adapted from Zha and Lackner 2010.  
    
AKT plays a key role in metabolism, growth, survival and proliferation. It promotes survival 
by directly phosphorylating the pro-apoptotic proteins BAD (Fig. 4) and procaspase-9 
resulting in their inactivation. AKT also phosphorylates MDM2, which sequesters p53 in the 
cytoplasm where it is degraded and, phosphorylates IKK which facilitates the activation of 












by AKT through various mechanisms: it activates β -catenin which associates with 
transcription factors resulting in expression of cyclin D1; it inhibits the FOXO transcription 
factors which are responsible for transcription of cell cycle regulatory proteins; and it also 
phosphorylates cell cycle inhibitors p21 and p27 leading to their translocation to the 
cytoplasm (Wickenden & Watson 2010; Steelman et al. 2011). AKT stimulates translation of 
protein, which is essential for growth, by phosphorylating tuberous sclerosis complex 2 
(TSC2), thereby preventing the formation of the TSC1:TSC2 complex (Steelman et al. 2011). 
mTORC1 becomes activated, which signals down to S6 kinase and eukaryotic translation 
initiation factor 4E binding protein (4E-BP1) allowing for protein translation and cell growth 
(Fig. 4) (LoPiccolo et al. 2007; Shukla et al. 2008). Considering that IGF-1R plays such a 
crucial role in metabolism and growth a tight regulation is required to maintain homeostasis. 
When the activity of this receptor is deregulated, diseases like diabetes and cancer occur. 
 
 
1.4.1 IGF-1R as a target in cancer 
 
The importance of AKT in cancer cell biology is evident when considering that most cancers 
display dysregulation of many AKT-regulated processes, including glucose metabolism and 
protein synthesis. Mutations or upstream RTK activity results in deregulation and constitutive 
activation of the PI3K/AKT pathway facilitating the growth, proliferation and survival of 
numerous cancers (Chen et al. 2005). IGF-1R is overexpressed in breast cancer biopsies 
(Knowlden et al. 2005), in pancreatic cancer (Moser et al. 2008) and in >90% of colorectal 
cancer (CRC) (Höpfner et al. 2006). Expression levels of IGF-1 and IGFBP-3 were found to 
correlate with increased risk and poor survival of pancreatic and other cancers (Cao et al. 












reported to increase the risk of secondary primary tumours (SPTs) in cancer of the head and 
neck, breast, lung, colon and prostate (Slomiany et al. 2006). IGF-1R has also been 
implicated in resistance to chemotherapeutic agents, and chemoresistant colorectal cancers 
display increased levels of total and activated IGF-1R (Chakraborty et al. 2008; Dallas et al. 
2009).  
Despite being strongly associated with transformation and drug resistance no mutations have 
been identified in the IGF-1R gene (Cao et al. 2008) and only duplication of gene copy 
number of IGF-1R or IGF is shown to associate with cancer (Massoner et al. 2010). 
Mutations within the PI3K pathway have been reported in roughly 30% of all cancers, with 
PTEN being the most common protein mutated in this pathway (Yi et al. 2005). Other 
mutations include point mutations in PI3KCA (p110α), AKT2 and 3-phophoinositide-
dependent protein kinase 1 (PDK1) and amplifications of AKT2 and IRS-2 (Shaw & Cantley 
2006). Aside from mutations within the PI3K pathway there are also feedback inhibitory 
loops which control protein expression and activity. Evidence suggests that PTEN can 
regulate the expression of IGF-1R, IGF-II and IGFPB3 in gastric adenocarcinoma cells (Yi et 
al. 2005). PKCδ was reported to activate mTOR, which increased IGF-1R expression in 
pancreatic cancer (Kwon et al. 2009). This activated an autocrine loop. mTOR occurs as two 
complexes, either the rictor mTORC2 or raptor mTORC1 complex. The rictor mTORC2 
complex activates AKT and thus the balance between mTORC1/2 affects AKT activity 
(Kurmasheva & Houghton 2006). Cao et al. (2008) reported that overexpression of 
constitutively active AKT resulted in significantly reduced phosphorylation of endogenous 
AKT, suggesting AKT feedback autoinhibition. Supporting this is the observation that in the 
presence of nutrients when insulin activation is prolonged, PI3K and AKT activity is 
downregulated (Shaw & Cantley 2006). Recent evidence also suggests that AKT has 












1.4.2 IGF-1R and EGFR crosstalk and drug resistance  
 
Aside from reports suggesting that the IGF-1R pathway can regulate itself and other RTK 
pathways, others indicate that IGF-1R can also transactivate and/or associate with other 
RTKs like EGFR. Meng et al., 2007 found that in vascular smooth muscle cells (VSMC) 
IGF-1R activated EGFR resulting in cell proliferation and this activation was dependent on 
ROS production. In colon carcinoma cells, IGF stimulation activated the IGF-1R/PI3K 
pathway resulting in TGFα production and EGFR activation (Hu et al. 2008). In COS-7 cells, 
stimulation with IGF resulted in activation of MMPs, which consequently cleaved HB-EGF 
resulting activation of EGFR, this could be inhibited by MMP inhibitors and neutralizing HB-
EGF antibodies (Roudabush et al. 2000). In breast cancer cell lines Riedemann et al., (2007) 
observed EGFR:IGF-1R heterodimers using immunoprecipitation. IGF-1R reportedly also 
associated with HER2 in breast cancer cells suggesting that IGF-1R association is not 
restricted to EGFR (Chakraborty et al. 2008). Therefore considerable evidence points in the 
direction of RTKs, like EGFR and IGF-1R, having the ability to transactivate each other in 


















1.5 Chemokines and their cognate Receptors  
 
Chemokines are small low molecular weight (8-17KDa) proteins that play important roles in 
infection, inflammation and the response of tissue to environmental external stimuli 
(Lazennec & Ann Richmond 2010). They serve as chemoattractants and recruit leukocytes to 
sites of inflammation. Chemokines can be divided into four sub families: C; CC; CXC and 
CX3C chemokines based on the spatial distribution of key cysteine residues in the N terminus 
(Bizzarri et al. 2006). CC and CXC chemokines comprise the majority of known chemokines 
(approximately 50). CXC chemokines can further be divided into two groups namely ELR+ 
and ELR- chemokines based on the presence of a Glutamine Leucine Arginine (ELR) motif 
(Addison et al. 2000; Keane et al. 2004). The ELR+ CXC chemokines promote angiogenesis, 
metastasis, survival and proliferation of tumour cells and include CXCL1, CXCL2, CXCL3, 
CXCL5, CXCL6, CXCL7, CXCL8 and CXCL12 (Table 1) (Catusse et al. 2003; Strieter et 
al. 2006; Balestrieri et al. 2008). CXC chemokines lacking the ELR motif are angiostatic, 
since they inhibit angiogenesis, proliferation and migration. ELR- chemokines include 
CXCL4, CXCL9, CXCL10 and CXCL11 while the function of the other chemokines, 
CXCL13-17, are less clear (Table 1) (Balestrieri et al. 2008). ELR+ or ELR- chemokines 
bind to their receptors commonly found on neutrophils; lymphocytes; endothelial and 












Adapted from Balestrieri et al., 2008.  














A group of plasma membrane receptor proteins termed G-protein coupled receptors (GPCRs), 
of which 18 have been described thus far, recognize and bind chemokines with various 
affinities (Kakinuma & Hwang 2006; Raman et al. 2007). Certain chemokines make use of 
the same receptors suggesting that redundancies exist in their function (Kakinuma & Hwang 
2006). All angiogenic (ELR+) chemokines bind the common receptor CXCR2 with the 
exception of CXCL8 which binds both CXCR1 and CXCR2, and CXCL12 which binds 
CXCR4 and CXCR7 (Table 1) (Burger et al. 2005; Mestas et al. 2005; Balestrieri et al. 
Table 1. Human chemokines and chemokine receptors
Systematic name Synonyms Specific receptor
CXC Chemokines
CXCL1 Groα, MGSA-α, NAP-3 CXCR1,2
CXCL2 Groβ, MIP-2α, MGSA-β, CINC-2α CXCR2
CXCL3 Groγ, MIP-2α, CINC-2β CXCR2
CXCL5 ENA-78 CXCR2
CXCL6 GCP-2 CXCR1,2
CXCL7 LDGF-PBP, CTAPIII, NAP-2, CXCR1,2
PF4, MDGF, LDGF, β-TG
CXCL8 IL-8, NAP-1, MDNCF, GCP-1 CXCR1,2
CXCL4 PF4 CXCR3A, 3B
CXCL4V1 CXCR3A, 3B
CXCL9 MIG CXCR3B
CXCL10 IP-10, CRG-2 CXCR3B
CXCL11 I-TAC, β-R1, IP-9 CXCR3B
CXCL12 SDF-1α/β, PBSF CXCR4,7
CXCL13 BCA-1, BLC CXCR5
CXCL14 BRAK, Bolekine Unknown 
CXCL16 SRPSOX CXCR6 












2008). CXCR2, a member of the GPCR family, is a 360 amino acid glycoprotein containing 7 
transmembrane domains separated by 3 intracellular and 3 extracellular loops (Chapman et 
al. 2009; Lagerström & Schiöth 2008). The predicted molecular weight of CXCR2 is 40 kDa, 
however, when it is phosphorylated a shift in size occurs which may represent receptor 
degradation (Mueller et al. 1997; Schraufstätter et al. 1998). CXC receptors share 25-80% 
homology and CXCR2 is 78% homologous to CXCR1 at the amino acid level, with major 
differences located at the amino terminus, the carboxyl terminus and the second extracellular 
loop (Addison et al. 2000; Chapman et al. 2009). Numerous cell types including 
keratinocytes, fibroblasts, endothelial cells, neutrophils, macrophages, monocytes and 
leukocytes express CXCR2 with its functional relevance being more clearly associated with 
migration/chemotaxis of immune cells to an immune response and sites of inflammation 
(Auten et al. 2001; Varney et al. 2003; Ho et al. 2006; Rigamonti et al. 2008; Yang et al. 
2010).  
Ligand binding to CXCR2 results in the activation of guanine nucleotide-binding proteins (G 
proteins) associated with the receptor, which activate phospholipase C (PLC). PLC in turn 
catalyzes the conversion of target phospholipids to diacylglycerol and inositiol triphosphate 
(Fig. 5) resulting in calcium mobilisation which is important for migration of neutrophils 
(Yang et al. 1999; Fan et al. 2003; Sai et al. 2006; Chapman et al. 2009). G proteins (Gαβγ) 
also relay CXCR2 signals down the Ras/MAPK/ERK1/2 pathway resulting in translocation 
of ERK1/2 to the nucleus where E2F, NF-κB and activator protein transcription factors are 
activated leading to transcription of numerous genes involved with cell proliferation as 
described earlier for MAPK signalling (Fig. 5) (Waugh & Wilson 2008; Yang et al. 2010). 
Silencing of CXCR2 in ovarian cancer cells resulted in increased expression of p21 while 
cyclin D1, cyclin A, cyclin B1, CDK2 and CDK6 levels were decreased suggesting that 












CXCR2 leads to increased mTORC1 activity resulting in protein translation by 4E-BP and S6 
kinase as previously described for AKT signalling (Waugh & Wilson 2008). Cell polarization 
towards a chemoattractant via actin nucleation and focal adhesion assembly are also 
important events downstream of PI3K/AKT essential for chemotaxis (Yang et al. 1999; 
Waugh & Wilson 2008). The MAPK and PI3K pathways are major downstream targets of 
CXCR2 since in many cell types stimulation of CXCR2 results in MAPK and PI3K 
signalling but barely activates stress kinases p38 and JNK (Yang et al. 1999; Waugh & 
Wilson 2008; Zhao et al. 2004; Sai et al. 2006). CXCR2 is rapidly internalized under 
conditions where the receptor has bound ligand, at a rate faster than that for CXCR1 
(Schraufstätter et al. 1998; Neel et al. 2005). Once bound to ligand CXCR2 is internalized in 
clathrin-coated pits with the assistance of arrestins, and is targeted for recycling or 




















Reports have linked aberrant internalization, degradation and recycling of GPCRs to disease 
states. The accumulation of the GPCR v2 vassopressin receptor as a result of desensitization 
and internalization results in nephrogenic diabetes insipidus (Wagener et al. 2009). Evidence 
exists that CXCR2 can drive cutaneous inflammation in skin carcinogenesis by the 
recruitment of neutrophils (Cataisson et al. 2009). Overexpression of CXCR2 in NIH 3T3 
Figure 5: CXCR1/2 activation by Interleukin 8 (IL-8) and downstream signalling 
Binding of IL-8 to its cognate receptors CXCR1 and CXCR2 results in phosphorylation of serine and threonine 
residues. This allows for the recruitment of guanine nucleotide-binding proteins (Gαβγ) which activates 
phosphatidyl inositol 3’ kinase (PI3K), Phospholipase C (PLC) and RasGTP. Downstream signalling pathways 
are involved with calcium mob lization, gene expression, protein synthesis and cytoskeleton dynamics. From 













cells in vitro leads to cell transformation (Burger et al. 2005). Epithelialisation and 
neovascularisation which involves recruitment of neutrophils are also mediated by CXCR2 
during wound repair (Devalaraja et al. 2000). ELR+ chemokines attract leukocytes to sites of 
inflammation and elicit an immune response. Cells of the immune system respond to this 
increasing gradient of ELR+ chemokines and arrest at the site of tissue damage or infection 
(Svensson et al. 2008). Overexpression or deregulation of ELR+ chemokines has been linked 
to diseases such as arthritis, diabetes, Alzheimer’s, asthma, pulmonary diseases and cancer 
(Aggarwal et al. 2006). Chronic inflammation of the intestine termed ulcerative colitis (UC) 
involves accumulation of leukocytes in the mucosa of the colon. Not surprisingly, CXCL8 
and CXCR1/2 expression was found elevated in patients with UC (Bizzarri et al. 2006). 
Pulmonary diseases such as cystic fibrosis and asthma have an increased concentration of 
neutrophils associated with the inflammatory environment of the disease. Elevated levels of 
CXCL8 and CXCR2 have been linked to pulmonary diseases (Chapman et al. 2009). 
Evidence suggests that CXCR2 promotes autosomal dominant polycystic kidney disease 
(ADPKD) and liver cyst growth (Amura et al. 2008).  The irregular production of 
chemokines and their receptors in the tumour environment results in recruitment of 
leukocytes which can contribute as much as 70% of the tumour mass (Yan et al. 2006). 
Chemokine receptors found associated with tumours include: CXCR2 important for 
angiogenesis; CCR2 responsible for recruitment of macrophages in the tumour micro 
environment; CCR7 which aids metastasis into sentinel lymph nodes which produce CCR7 
ligand CL21; and CXCR4 involved in metastatic spread of numerous tumours (Raman et al. 
2007).  There is strong evidence that deregulation of chemokines and their receptors play a 














1.5.1 Chemokines and CXCR2 in Cancer 
 
Chemokines and their receptors are important in host mediated defence against infections, 
environmental stimuli and mechanical injury by eliciting an inflammatory response. 
Furthermore, numerous reports strongly suggest that inflammation and cancer are closely 
related processes, since tumours are often surrounded by cells of the immune system and 
chemokine ligands, and/or receptors are elevated in most cancers (Aggarwal et al. 2006; 
Wislez et al. 2006; Acosta & Gil 2009; Cataisson et al. 2009; Varney et al. 2011). 
Chemokine expression has also been linked to tumourogenesis and angiogensis of tumours. 
The chemokines IL-1, IL-6 and IL-8 are reported to promote growth and metastasis of 
various cancers, and inhibition of IL-8 in NSCLC xenografts was shown to reduce vascular 
density and tumour volume by 40% (Watanabe et al. 2002; Aggarwal et al. 2006). In a 
murine squamous cell carcinoma model, overexpression of GROα resulted in increased 
infiltration of leukocytes to the tumour site and increased vascularity (Loukinova et al. 2000). 
The evidence that ELR+ chemokines are associated with cancer growth and angiogenesis 
suggests that their receptors also play a role linking autocrine or paracrine ligand cues with 
intracellular signalling. Most ELR+ chemokines bind the common receptor CXCR2 and 
reports have observed a functional role of CXCR2 in certain cancers. 
 
ELR+ chemokines can act in an autocrine loop in melanoma and pancreatic cancer where 
NF-κB drives transcription of IL-8 which activate the receptors CXCR1/2 (Wente et al. 2006; 
Luppi et al., 2007). Melanoma cells displaying elevated levels of IL-8 and CXCR2 have 
reduced proliferation and angiogenesis when targeted with CXCR2 small molecule inhibitors 
(Singh et al. 2009; Yang et al. 2010). In pancreatic cancer patients, CXCL5 and CXCL8 are 












in pancreatic cancer xenografts resulted in significantly reduced tumour volume and 
microvessel density (Matsuo et al. 2009). Mestas et al., (2005) observed elevated CXCR2 
ligands in the plasma of renal cell carcinoma (RCC) patients versus that of healthy control 
individuals. Furthermore, this group showed that RCC tumour volume is significantly 
reduced when xenografted into CXCR2-/- vs CXCR2+/+ mice. A similar observation was 
reported for lung cancer xenografts in CXCR2-/- mice (Keane et al. 2004). A previous study 
in our laboratory suggested the presence of a CXCR2/GROβ autocrine loop in oesophageal 
cancer cells since silencing GROβ expression resulted in reduced cell proliferation in vitro 
(Wang et al. 2006).   
 
This review has shown that EGFR, IGF-1R and CXCR2 are frequently dysregulated in many 
cancers, and that they may contribute to the tumourigenic state. The aim of this study was to 
characterise the role of EGFR, IGF-1R and CXCR2 in OSCC cultured cells with the 
following main objectives being: 
• determining the expression of EGFR, IGF-1R and CXCR2 in OSCC cell lines  
• verify whether receptors are functional and activate downstream MAPK and AKT 
pathways 
• evaluate the effect of receptor inhibition or silencing on cell proliferation and survival  



















Epidermal Growth Factor Receptor and Type-1 Insulin-
like Growth Factor Receptor as potential therapeutic 
targets for Oesophageal Cancer 
	  
2.1 Introduction 
The epidermal growth factor receptor (EGFR) is commonly overexpressed in 30-80% of 
OSCC cases as well as in other cancers of epithelial origin (Tew et al. 2005; Weihua et al. 
2008). Overexpression of EGFR in oesophageal cancer correlates with poor patient survival 
and increased tumour aggressiveness making it an interesting target for OSCC therapy. 
However this receptor has been targeted in other cancers with patients showing limited 
response to therapy (Cohen et al. 2005; Ono & Kuwano 2006; Sharma et al. 2007). A few 
clinical trials have explored the potential of EGFR as a target in OSCC but these results are 
difficult to interpret given that most patients in these studies present with advanced stages of 
disease, and some had already undergone surgery or chemotherapy as a first line of treatment. 
Furthermore, patient numbers are often small, patient cohorts frequently consist of both SCC 
and AC, and EGFR expression levels were not assessed in patients prior to initiation of 
treatment (Janmaat et al. 2006; Ferry et al. 2007; Sudo et al. 2007; Dragovich & Campen 
2009). The general poor response to EGFR targeted therapy suggests that there may be other 
underlying processes either compensating for loss of EGFR function or that EGFR 












In numerous cancers the insulin-like growth factor receptor (IGF-1R) has been implicated in 
the development of drug resistance both in cancer cell line models and in the clinical setting. 
Non-small cell lung cancer (NSCLC) patients resistant to EGFR-targeted therapy, gefitinib 
and erlotinib, reportedly display elevated levels of active IGF-1R,  and inhibition of IGF-1R 
has been found to restore sensitivity to gefitinib or erlotinib in resistant NSCLC cell lines 
(Morgillo et al. 2007a; Morgillo et al., 2007b). Similar observations have been reported in 
breast cancer patients resistant to the HER2 monoclonal antibody, transtuzumab 
(Chakraborty et al. 2008). Although elevated levels of IGF-1R correlated with poor survival 
in OSCC patients, little is known regarding its potential as a target in OSCC (Sutter et al. 
2006). Evidence in the literature regarding the important role that EGFR and IGF-1R play in 





















Figure 2.1: EGFR and IGF-1R expression in OSCC cell lines.  
OSCC cells were cultured to 60-70% confluency and protein was harvested. A total of 40 µg of protein lysate 
from each cell line was separated by SDS-PAGE electrophoresis and transferred to nitrocellulose membrane. 
The membrane was probed with antibodies recognizing total EGFR and IGF-1R. Beta-tubulin was used as a 







































2.2.1 EGFR and IGF-1R expression and signalling 
Since many studies reported that EGFR and IGF-1R are overexpressed in OSCC tissue 
compared to adjacent normal tissue (Imsumran et al. 2007; Sutter et al. 2006) we proceeded 
to determine the expression of EGFR and IGF-1R in a panel of cultured OSCC cell lines. 
Oesophageal cancer cell lines, established from primary OSCC tumours, were cultured and 
the protein harvested for western blot analysis. As observed in Figure 2.1, EGFR and IGF-1R 
were expressed in all cell lines albeit at different levels. WHCO1 and WHCO6 were chosen 
as model cell lines to explore EGFR and IGF-1R and their associated signalling pathways 
since these cell lines have been routinely used in our laboratory to further our understanding 
of OSCC cell biology (Whibley et al. 2005; Wang et al. 2006; Whibley et al. 2007; Wang et 

















Since both receptors were present in the cell lines, we next determined if these receptors were 
functional and capable of activating their downstream targets. WHCO1 and WHCO6 cells 
were stimulated with 20 ng/ml EGF or 50 ng/ml IGF-1 for the indicated time periods and 
protein was harvested for western blot analysis. Receptor activation was visualised by 
probing with antibodies directed to the phosphorylated forms of EGFR (anti-pTyr1173) and 
IGF-1R (anti-pTyr1131). EGFR was rapidly activated by EGF and its activity could be 
measured up to 1 hour post-treatment, after which activity was lost (Fig. 2.2A). This was 
consistent with reports for EGFR activation and desensitization after stimulation with ligand 
(Burke et al. 2001). Similarly, ERK1/2 was strongly activated by EGF treatment while AKT 
activation increased slightly, similar to previous reports that EGFR strongly regulates 
ERK1/2 activity compared to AKT activity (Cao et al. 2008; Hu et al. 2008; Villanueva et al. 
2010). Total EGFR levels were also reduced by 3 hr and 8 hr post-EGF treatment in both 
WHCO1 and WHCO6 cells, suggesting that prolonged stimulation with EGF resulted in EGF 
receptor degradation (Appendix Fig. A1). Protein levels of IGF-1R, AKT and ERK1/2 
remained unchanged when cells were treated with EGF (Appendix Fig. A1). The signalling 
results observed here, suggested that functional EGFR was capable of relaying signals down 
the MAPK-ERK1/2 and PI3K-AKT pathway (Fig. 2.2A).  
Stimulation with IGF-1 resulted in a sustained activation of IGF-1R and its downstream 
target AKT indicating that this receptor was also functional in the model OSCC cell lines 
WHCO1 and WHCO6 (Fig. 2.2B). The sustained IGF-1R activity is consistent with reports 
that IGF-1R activation is stable (Hansen et al. 1996). Furthermore, total IGF-1R levels also 
remained unchanged in the presence of IGF-1 treatment (Appendix Fig. A1). Several 
interesting observations were noted in the response of the cells to treatment with EGF and 
IGF. Firstly, EGF stimulation resulted in the early transient activation of IGF-1R – more 












activation of EGFR (Fig. 2.2B). Lastly, a strong decrease in pERK1/2 was noted when cells 
were stimulated with IGF-1 (Fig. 2.2B). These observations were further addressed to 
determine if there were any interactions between the EGFR and IGF-1R pathways in OSCC 
cell lines, as suggested by literature reports for other tissues (Roudabush et al. 2000; Meng et 
















































































Figure 2.2:  EGF and IGF-1 stimulation in OSCC cell lines. 
 WHCO1 and WHCO6 cells were seeded at 3 x 105 cells per 60 mm dish. Cells were serum starved for 1hr in 
serum free DMEM followed by stimulation with 20 ng/ml EGF or 50 ng/ml IGF-1 in serum free DMEM for the 
indicated times. Protein was harvested and subjected to western blot analysis using antibodies specific for pIGF-
1R, pEGFR, pAKT and pERK1/2 (A and B). The last lane in A and B represents cells stimulated with either 20 
















































Crosstalk from IGF-1R to EGFR has been reported in other cancers as mentioned earlier. 
However, when OSCC cells were stimulated with IGF-1 we could not detect an increase in 
pEGFR despite the positive response observed in the lane of EGF-stimulated cells (Fig 2.2B). 
Ligand binding to EGFR results in dimerization and autophosphorylation of Tyr residues, 
with pTyr1173 being the major phosphorylation site indicative of fully active EGFR (Mandic 
et al. 2006). Seeing that the pEGFR antibody used here only recognised pTyr1173, we could 
not exclude the possibility that EGFR may be phosphorylated at other sites in response to 
IGF-1 treatment. To address this problem, WHCO1 cells were stimulated with IGF-1 for 10 
min or 3 hr; and with EGF ligand for 10 min as a positive control. Protein was harvested and 
subjected to immunoprecipitation using anti-EGFR, followed by western blotting. A pan-
pTyr antibody, readily detected pEGFR in the EGF stimulated cells (Fig. 2.3, lane 2), 
however, no increase in pEGFR was observed in the IGF-1 treated cells (Fig. 2.3, lanes 3 and 
4). EGFR was present at approximately equal levels in all lanes indicating that the receptor 
was successfully immunoprecipitated in each pull down experiment. This result confirmed 




























Our observation that IGF-1R was rapidly phosphorylated in response to EGF treatment in 
OSCC cell lines (Fig. 2.2A) has not been reported previously.  We observed the same result 
in two other OSCC cell lines (WHCO5 and KYSE 180), suggesting that this phenomenon 
was not an artefact associated with specific cell lines (appendix Figure A2). We thus sought 
to determine if the activation of IGF-1R was dependent on the activation of EGFR or if EGF 
directly activated IGF-1R. Cells were pre-treated with the EGFR kinase domain inhibitor, 
AG1478, for 30 min followed by stimulation with EGF. Protein was harvested and analysed 
by western blot analysis using antibodies specific for pEGFR and pIGF-1R. EGF-induced 
phosphorylation of EGFR was completely abrogated in the presence of AG1478 indicating 
that the concentration of inhibitor used was sufficient to inhibit EGFR activity (Fig. 2.4).  
Furthermore co-treatment of cells with EGF and AG1478 also prevented the transient EGF-
induced phosphorylation of IGF-1R, indicating a requirement for EGFR activity in this 
crosstalk. 
Figure 2.3:  EGFR activity in the presence of EGF or IGF-1 in WHCO1 OSCC cells. 
A total of 3 x 105 WHCO1 cells were serum starved followed by treatment with either 20 ng/ml EGF or 50 
ng/ml IGF-1 for the indicated time points in 60 mm dishes. Protein was harvested and 300 µg of protein was 
subjected to EGFR immunoprecipitation (Ippt). EGFR immunoprecipitates were subjected to western blotting, 
















































Figure 2.4:  EGFR and IGF-1R activity in the presence of EGF and EGFR kinase inhibitor AG1478.   
WHCO1 and WHCO6 cells were pre-treated with 1 µM EGFR kinase inhibitor AG1478 for 30 min followed by 
stimulation with 20 ng/ml EGF for the indicated time period. Cell lysates were subjected to western blot 
analysis using antibodies towards pEGFR and pIGF-1R. Cells stimulated with either 20 ng/ml EGF (EGF+) or 
50 ng/ml IGF-1 (IGF+) for 10 to 30 min were used as positive controls.  
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The observation that IGF-1R was rapidly phosphorylated in response to EGF treatment, and 
that this phosphorylation was dependent on activated EGFR, suggested that EGFR could 
directly activate IGF-1R. Riedemann et al., (2007) reported the presence of EGFR/IGF-1R 
dimers in breast cancer cells. A similar interaction between these receptors in OSCC cells 
could in part, explain the EGF-induced phosphorylation of IGF-1R that we observed.  To 
further investigate an association between EGFR and IGF-1R, cells were cultured to 70% 
confluency and protein was harvested and incubated with an EGFR antibody overnight. 
EGFR was pulled down with protein-A agarose beads and subjected to western blot analysis 
using antibodies against EGFR and IGF-1R. We performed EGFR immunoprecipitations in 
several OSCC cell lines to determine the presence of EGFR/IGF-1R hetero-dimers. When 
protein lysate was incubated with beads only, as a negative control, we observed no non-
specific bands corresponding to EGFR and IGF-1R. Both EGFR and IGF-1R were present in 
all EGFR immunoprecipitates suggesting that these receptors associate with each other in all 





































2.2.2 IGF-1R-AKT negatively regulates the EGFR-ERK1/2 axis 
 
As previously mentioned, activation of the IGF-1R pathway with IGF-1 resulted in a sharp 
decrease in pERK1/2 levels in WHCO1 and WHCO6 OSCC cells (Fig. 2.2B). This 
observation was reproducible in multiple experiments and in another OSCC cell line, 
WHCO5 (Appendix Fig. A3). This suggested that activation of the IGF-1R pathway 
negatively regulated ERK1/2 activity under these conditions. Considering this observation, 
Figure 2.5: EGFR immunoprecipitation in OSCC cell lines.  
Protein harvested from OSCC cell lines was subjected to EGFR immunoprecipitation (IP). Protein lysate (300 
µg) was incubated with EGFR primary antibody overnight at 4oC with rotation. Protein-A agarose beads was 
added and incubated for 4 hr with rotation, EGFR was pulled down by centrifugation and analysed by western 
blotting using antibodies to EGFR and IGF-1R as indicated. A negative control (+Beads), consisting of protein 
lysate incubated with protein A beads in the absence of EGFR antibody, was performed in parallel to rule out 
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we questioned whether the inverse was true, hypothesising that inhibition of basal IGF-1R 
activity would result in increased levels of pERK1/2. At the time when these experiments 
were conducted most IGF-1R inhibitors that were commercially available were not very 
specific, and cross-reacted with the insulin receptor while the more specific inhibitors were 
under patent rights and could not be obtained. For this reason, cells that stably expressed 
IGF-1R shRNA or control non-specific shRNA were generated using a lentiviral system. 
WHCO1 and WHCO6 cells were infected with lentiviral particles containing IGF-1R specific 
shRNA or random shRNA, and transfected cells were selected by FACS analysis based on 
GFP positivity (as described in methods section). Cells were cultured and protein harvested 
under normal unstimulated culture conditions for western blot analysis. Total IGF-1R and 
pAKT levels were reduced by ≥50%, and both EGFR and ERK1/2 levels displayed increased 














































Figure 2.6:  IGF-1R knockdown in WHCO1 and WHCO6 OSCC cell lines.   
WHCO1 and WHCO6 cells were infected with lentiviral particles containing either Ctrl or IGF-1R shRNA 
expression vectors and transfected cells were collected using a cell sorter. Protein was harvested from Ctrl and 
IGF-1R shRNA cells and analyzed by western blot analysis using antibodies to IGF-1R, pEGFR, EGFR, 



























































The decrease in pERK1/2 levels associated with IGF-1 treatment, and the increase in 
pERK1/2 levels observed when IGF-1R was knocked down suggested the presence of an 
IGF-1R driven, negative feedback loop impinging on the Ras/ERK1/2 MAPK pathway. 
Recent evidence has implicated AKT in negatively regulating receptor tyrosine kinases that 
include Her3, Her4 and InsR (Chandarlapaty et al. 2011). Furthermore, evidence suggests 
that AKT activity negatively regulates Raf, one of the upstream signalling molecules in the 
Ras-Raf-Mek-ERK1/2 pathway (Moelling et al. 2002; McCubrey et al. 2007). We used 
another approach (an AKT inhibitor) to further explore the link between the IGF-1R/AKT 
and EGFR signalling pathways in OSCC. Parental WHCO1 and WHCO6 cells were treated 
with 20 µM AKT VIII trifluoroacetate salt for the indicated time points, protein was 


















































Figure 2.7: Effect of AKT inhibitor (AKT VIII trifluoroacetate salt) on pEGFR and pERK1/2 in WHCO1 
and WHCO6 OSSCC cell lines.   
WHCO1 and WHCO6 cells (3 x 105 cells per 60 mm dish) were treated with 20 µM AKT inhibitor (AKT VIII 
trifluoroacetate salt) for the indicated times and protein was harvested. The cell lysates were analyzed by 
western blot analysis using antibodies specific for pAKT, pEGFR and pERK1/2.  
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The AKT inhibitor clearly blocked the activation of AKT for at least 24 hr in WHCO1 cells 
and for 48 hr in WHCO6 (Fig. 2.7). AKT inhibition was associated with a significant increase 
in pERK1/2 levels in both cell lines. However AKT inhibition had no effect on pEGFR 
levels. This suggested that in OSCC cells AKT signalling regulated ERK1/2 activity but 
exerted no inhibition on EGFR activity or expression. 
 
To exclude the possibility that IGF-1R knockdown cells secreted elevated levels of EGFR 
ligand, hence activating EGFR as observed in Figure 2.6, we treated wild type WHCO1 and 
WHCO6 cells with conditioned medium from the IGF-1R knockdown cells. Briefly, WHCO1 
and WHCO6 cells expressing Ctrl or IGF-1R shRNA were cultured to 60-70% confluency. 
The conditioned medium harvested from WHCO1 and WHCO6 Ctrl and IGF-1R shRNA 
cells was transferred to WHCO1 and WHCO6 parental cell lines respectively. In both 
WHCO1 and WHCO6 parental cells no increase in pEGFR was observed following 
incubation in conditioned medium from Ctrl or IGF-1R shRNA transfected cells (Fig. 2.8). 
This suggests that the IGF-1R shRNA cells do not produce increased levels of EGFR ligands, 
and indicates that the process responsible for increased EGFR activation in IGF-1R 































The work described thus far has characterized a part of the EGFR and IGF-1R signalling 
pathway in OSCC cell lines, allowing the following important observations: EGFR and IGF-
1R are functional and co-associate in several OSCC cell lines; EGFR rapidly activates IGF-
1R within ten min when cells are stimulated with EGF and this activation requires EGFR 
kinase activity; lastly IGF-1R signalling negatively regulates EGFR/ERK1/2 activity as IGF-
1 treatment reduced pERK1/2 levels and IGF-1R knockdown resulted in increased pEGFR 
and pERK1/2 levels. This evidence of significant cross-talk between the EGFR and IGF-1R 
pathways in OSCC prompted us to investigate the potential of EGFR and IGF-1R, as drug 
targets in OSCC cell lines.   
Figure 2.8:  EGFR activity in parental WHCO1 and WHCO6 cells in the presence of Ctrl or IGF-1R 
shRNA conditioned medium.   
WHCO1 and WHCO6 Ctrl and IGF-1R shRNA cells were grown to 60-70% confluency and cells were 
incubated for 16 hr with serum-free DMEM medium. Conditioned media (CM) (serum free DMEM) from 
WHCO1 and WHCO6 Ctrl and IGF-1R shRNA transfected cells were added to the respective parental (wt) 
WHCO1 and WHCO6 cells for 10 min and protein was harvested. Cell lysate was analyzed by western blot 
probing for pEGFR.  WHCO1 cells treated with 20 ng/ml EGF for 10 min was used as a positive control for 
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2.2.3 EGFR and IGF-1R as drug targets in OSCC 
 
After incubating OSCC cultured cells and normal cultured skin fibroblast cells with varying 
concentrations of AG1478 for 48 hr, the IC50 was determined using the MTT assay. An IC50 
value of 13.6 µM for WHCO1 and 11.9 µM for WHCO6 OSCC cells was obtained while 
















Cell Line IC50 in µM Confidence interval 
WHCO1 13.6 10.8 -17.2 
WHCO6 11.9 7.4 - 19 
DMB >100 undefined 
FG0 75 43.2 - 130 
Table 2:  Drug sensitivity of OSCC cells and normal fibroblast cells to AG1478   
WHCO1 (A) and WHCO6 (B) OSCC cells, and normal skin fibroblasts DMB (C) and FGo (D) were plated at a 
density of 5000 cells per well in 96 well plates and were treated with a range of concentrations of AG1478 to 
determine the IC50 values. Cells were incubated with AG1478 for 48 hr followed by the MTT assay. The 














Previously we showed that 1 µM of AG1478 was sufficient to inhibit EGFR activation in the 
presence of EGF (Fig. 2.4) and we thus determined the effect of low concentrations of 
AG1478 on the cell cycle and proliferation. Cells were treated with 1 µM AG1478 and 
proliferation was monitored by MTT assay. Cell proliferation was reduced by 30-40% in 
WHCO1 and WHCO6 cells treated with inhibitor compared to untreated cells (p ≤ 0.005) 
(Fig. 2.9). The decrease in cell proliferation was consistent with the strong cell cycle arrest 
observed when the cell cycle profile was analysed. The results in appendix Figure A4, show 
that 1 µM AG1478 induces a G1 cell cycle block after 48 hr, with a nearly complete loss of 











































Figure 2.9:  Cell proliferation of WHCO1 and WHCO6 OSCC cells in the presence of AG1478   
WHCO1 and WHCO6 cells were plated at a density of 1500 cell per well in 96 well plates and treated with 1 
µM AG1478 in triplicate. Growth was monitored over a 6 day time period by means of the MTT assay and the 
corrected absorbance values of untreated and treated cells were plotted in a line graph in Microsoft Excel®. 
















To confirm that the growth inhibitory effects of AG1478 were due to inhibition of EGFR, an 
siRNA approach was also used. WHCO1 cells were treated with control or EGFR siRNA 
over a period of three days to transiently reduce levels of EGFR protein. EGFR levels were 
significantly reduced for 48 hr but returned to normal levels after 72 hr in WHCO1 cells 
transfected with EGFR siRNA (Fig. 2.10). This is consistent with the transient nature of 










WHCO1 and WHCO6 cells were treated with Ctrl or EGFR siRNA and growth was 
monitored by MTT assay over a period of time. EGFR siRNA transfected cells displayed a 
transient reduction in proliferation compared to cells transfected with control siRNA (Fig. 
2.11). The transient nature of the reduction in proliferation could be attributed to the re-
expression of EGFR protein after 72 hr (Fig. 2.10).  
 
Figure 2.10:  EGFR transient knockdown  
WHCO1 cells were seeded in 35 mm dishes at a density of 1.2 x 105 cells per dish. The following day cells were 
transfected with 20 nM control or EGFR siRNA and protein was harvested at 24, 48 and 72 hr post-transfection. 
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Figure 2.11:  Proliferation of WHCO1 and WHCO6 cells treated with Ctrl or EGFR siRNA   
WHCO1 and WHCO6 cells were transfected with 20 nM Ctrl or EGFR siRNA in 60 mm dishes. The following 
day cells were re-plated at a density of 1500 cells per well in 96 well plates and cell proliferation was 
determined over a period of time using the MTT assay. The absorbance of Ctrl and EGFR siRNA treated cells 
was determined using a plate reader and plotted as a line graph in Microsoft Excel®. Each point was performed 













Taken together, results with the EGFR inhibitor and EGFR knockdown suggest that EGFR 
does contribute to proliferation of OSCC cells to some extent. However, whether or not 
EGFR is important for OSCC cell survival is still debatable, since cells were still viable when 
EGFR expression was knocked down, or when treated with sufficient AG1478 to completely 
abolish EGFR activation for six days.  
Given the cross-talk between EGFR and IGF-1R identified in the first part of this chapter, we 
proceeded to investigate the simultaneous targeting of EGFR and IGF-1R using the IGF-1R 
knockdown cells as a model. IGF-1R knockdown cells displayed a ≥50% reduction in levels 
of total IGF-1R with reduced downstream pAKT levels (Fig. 2.6). When cell proliferation 
was determined by means of the MTT assay similar growth rates were observed in IGF-1R 
shRNA transfected cells and Ctrl shRNA transfected cells (Fig. 2.12). Cell cycle analysis also 
revealed no significant changes in G1/S/G2 phases and these cells were indistinguishable 





























































































Figure 2.12:  Proliferation of Ctrl and IGF-1R shRNA cells   
WHCO1 and WHCO6 cells stably expressing Ctrl or IGF-1R shRNA were seeded at a density of 1500 cells per 
well in 96 well plates and proliferation was measured by means of MTT assay. The absorbance of WHCO1 and 
WHCO6 Ctrl and IGF-1R shRNA cells was determined using a plate reader and plotted as a line graph in 
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Our observation that IGF-1R knockdown cells displayed similar proliferation rates as control 
cells (Fig. 2.12), while displaying elevated EGFR/ERk1/2 pathway activity (Fig. 2.6) 
provided an interesting phenotype for further investigation using the EGFR inhibitor, 
AG1478. The MTT assay was conducted treating WHCO1 and WHCO6 Ctrl and IGF-1R 
shRNA cells with AG1478 to determine drug sensitivity. IGF-1R shRNA cells displayed a 
two- to three- fold increase in sensitivity to AG1478 compared to Ctrl shRNA cells (Fig. 
2.13). Furthermore when PARP cleavage (an indicator of apoptosis) was measured in cells 
treated with 3 µM AG1478, a similar two- to three-fold increase in PARP cleavage was 














Figure 2.13: Drug sensitivity of WHCO1 and WHCO6 Ctrl and IGF-1R shRNA transfected cells to 
AG1478 
WHCO1 and WHCO6 Ctrl and IGF-1R shRNA cells were plated at a density of 5000 cells per well in 96 well 
plates and were treated with a range of concentrations of AG1478 and drug sensitivity was determined after 48 
hr by means of the MTT assay. The absorbance was read with a multi plate reader at 595 nm and data was 
analysed using GraphPadPrism v3®. Each point was performed in triplicate and error bars represent STDEV. 
	  































Previous reports have implicated IGF-1R in providing survival signals to chemo-resistant 
cells (Chakraborty, Liang, & DiGiovanna, 2008; Dallas et al., 2009) which could explain the 
observed increased sensitivity of IGF-1R knockdown cells to AG1478 (Fig. 2.14).  We 
hypothesized that if IGF receptors were providing survival signals in OSCC cells, IGF-1R 
shRNA cells should also display an increased sensitivity to other chemotherapeutic 
compounds. WHCO1 control and IGF-1R shRNA cells were treated with cisplatin to 
determine the sensitivity to this drug (Fig. 2.15). Control and IGF-1R knockdown cells 
Figure 2.14: Effect of AG1478 on apoptosis in WHCO1 and WHCO6 Ctrl and IGF-1R shRNA cells  
A total of 3 x 105 WHCO1 and WHCO6 Ctrl and IGF-1R shRNA cells were seeded in 60 mm dishes. The 
following day cells were treated with 3 µM AG1478 for 24 and 48 hr. Protein was harvested and IGF-1R 
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displayed similar sensitivity to cisplatin (18.5 µM vs. 20.8 µM respectively) suggesting that 
reduction in IGF-1R expression had not sensitized the cells to cisplatin. Furthermore when 
WHCO1 and WHCO6 Ctrl and IGF-1R shRNA cells were treated with 10 µM cisplatin or 5 
µM doxorubicin for 24 or 48  hr, no further increase in PARP cleavage was observed in IGF-
1R knockdown cells (Fig. 2.16 A and B). Our data suggest that simultaneous disruption of 
EGFR and IGF-1R function could be more effective than inhibition of IGF-1R combined 
with other chemotherapeutic agents such as cisplatin or doxorubicin. However, this novel 



















Figure 2.15: Drug sensitivity of WHCO1 Ctrl and IGF-1R shRNA transfected cells to cisplatin 
WHCO1 Ctrl and IGF-1R shRNA cells were treated with a range of concentrations of cisplatin for 48 hr and 
drug sensitivity was determined by the MTT assay. The absorbance was read with a multi plate reader at 595 nm 
and data was analysed using GraphPadPrism v3®. Each point was performed in triplicate and error bars 
represent STDEV. 
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Figure 2.16: Effect of cisplatin or doxorubicin on apoptosis in WHCO1 and WHCO6 Ctrl and IGF-1R 
shRNA cells 
WHCO1 and WHCO6 Ctrl and IGF-1R shRNA cells were seeded in 60 mm dishes at a density of 3 x 105 cells 
per dish. The following day cells were treated with 10 µM Cisplatin (A) or 5 µM Doxorubicin (B), and 
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EGFR and IGF-1R both play important roles in cancer biology with overexpression of EGFR 
associated with poor prognosis in oesophageal and head and neck cancers (Tew et al. 2005) 
and IGF-1R overexpression associated with resistance to chemotherapeutic agents (Dallas et 
al., 2009). Furthermore, overexpression of EGFR in the normal immortalised epithelial 
keratinocyte cell line, EPC2 is sufficient to transform cells in vitro and in vivo (Kim et al. 
2006). EGFR overexpression in epithelial tissue of the epidermis results in hyperplasia and 
abnormal growth of cells (Okawa et al. 2007). However, understanding the biology of these 
receptors is complex, as a recent study revealed, with EGFR knockout mice dying soon after 
birth but transgenic mice expressing kinase deficient EGFR remaining fully viable (Weihua 
et al. 2008). A deeper understanding of the role of these receptors in oesophageal cancer is 
required before we can consider clinical applications of receptor targeting. In this study we 
investigated the role of EGFR and IGF-1R in OSCC cell biology evaluating their function 
and potential as drug targets. The focus of this study was to attain a better understanding of 
the role of EGFR and IGF-1R in OSCC as studies in other cancers provided evidence that co-
targeting these receptors simultaneously might be more beneficial than individual targeting.   
 
We demonstrated that both EGF and IGF-1 receptors were expressed in a panel of our OSCC 
cell lines. WHCO1 and WHCO6 cells were chosen as model cell lines as they have been 
extensively studied in our laboratory. Analysis of receptor functionality by means of ligand 
stimulation revealed that these receptors were functional in WHCO1 and WHCO6 cells with 
overlapping interactions either between receptors or regulation of their downstream signalling 
pathways. EGF treatment resulted in a rapid but transient activation of IGF-1R suggesting 












transactivates EGFR (Thomas et al. 2006; Meng et al. 2007; Hu et al. 2008). However, to our 
knowledge, no previous reports described EGFR as being capable of activating IGF-1R, 
making this a novel finding. Furthermore we observed that activation of the EGFR kinase 
domain was critical for IGF-1R activation by EGF, which suggested that EGFR and IGF-1R 
may associate with each other accounting for the rapid activation of IGF-1R. EGFR and IGF-
1R, despite belonging to different RTK families have been shown to associate when co-
expressed (Riedemann et al. 2007). Elevated receptor expression increases the likelihood of 
their association which has been observed in breast cancer and NSCLC, although in some 
breast cancers, EGFR and IGF-1R do not associate despite being expressed at elevated levels 
(Morgillo et al. 2007b; Riedemann et al. 2007). Furthermore, the association between EGFR 
and IGF-1R also occurs in non-cancerous tissue (e.g. mammary epithelial cells) and this 
association is involved with activating cell proliferation (Ahmad et al. 2004; Meng et al. 
2007; Jin & Esteva 2008). We observed that EGFR and IGF-1R co-immunoprecipitate in 
several OSCC cell lines under basal conditions, suggesting that association between EGFR 
and IGF-1R may commonly occur in OSCC. In cancer cells which often display elevated 
levels of these receptors, it is possible that dimerization may be advantageous by conferring 
increased sensitivity to bio-available ligands.  
 
We also observed that IGF-1 stimulation strongly reduced pERK1/2 levels in three of our 
OSCC cell lines suggesting that IGF-1R negatively regulates ERK1/2 activity.  This was 
supported by our observation that inhibition of AKT resulted in increased pERK1/2 levels 
and knockdown of IGF-1R increased pEGFR and pERK1/2 levels. Our data suggests that in 
OSCC cells the processes regulating EGFR/ERK1/2 activity may involve (at least in part) the 
IGF-1R/AKT axis. Recent evidence supports this theory that the IGF-1R/AKT pathway can 












including the HER family of receptors, erlotinib potentiated mTOR regulated translation of 
EGFR, loss of IGF-R increased expression of other kinases including EGFR, and IGF-1R 
activity was suggested to block basal pEGFR (Kuribayashi et al. 2004; Morgillo et al. 2007a; 
Huang et al. 2009; Chandarlapaty et al. 2011). The activation of EGFR in IGF-1R 
knockdown cells was not attributed to increased levels of EGFR ligands considering that 
parental cells displayed no increase in pEGFR when treated with IGF-1R knockdown 
conditioned medium. Morgillo et al., (2007b) also observed increased pEGFR levels when 
IGF-1R was inhibited. However, they do not explain this observation. Their reported 
observation, that IGF-1R inhibition resulted in increased pEGFR, could be in line with our 
data suggesting that IGF-1R activity regulates the EGFR/ERK1/2 axis. Furthermore, the 
observation that inhibition of AKT resulted in increased expression and activation of EGFR 
(Chandarlapaty et al. 2011) might be specific to certain cancers, since pEGFR levels did not 
increase in our cells when AKT was inhibited. Our data could suggest that IGF-1R regulates 
EGFR activity upstream of AKT.  
 
EGFR has been the focus of numerous studies over the past 20 years and inhibitors of this 
receptor were approved for clinical treatment of certain cancers. Epithelial cancers often 
display elevated EGFR expression but only in certain types of cancers like NSCLC and 
HNSCC has EGFR targeted therapy proven successful (Cohen et al. 2005; Ono & Kuwano 
2006; Sharma et al. 2007; Weihua et al. 2008). In this study we investigated the potential of 
EGFR as a target in OSCC cell lines because its overexpression was reported to correlate 
with patient survival. OSCC cells displayed drug sensitivity to AG1478 in the range of 10 
µM while normal skin fibroblasts were much less sensitive. Proliferation of cells using low 
concentrations of AG1478 or transient knockdown of EGFR resulted in a 30-40% reduction 












10-30% of OSCC patients treated with EGFR inhibitors displayed stable disease for 2-3 
months followed by tumour progression (Dragovich & Campen 2009). Similarly our 
observation that inhibition of EGFR activity, with low concentrations of AG1478 or siRNA, 
resulted in reduced proliferation but not significant apoptosis suggested that EGFR may 
contribute to proliferation but not be critical for OSCC cell survival.   
 
IGF-1R is commonly overexpressed in OSCC and evidence has implicated it in drug 
resistance (Mitsiades et al. 2004; Chakraborty et al. 2008). IGF-1R has been assessed as a 
target in vitro and in vivo in other cancers with promising results. Small molecule inhibitors, 
NVP-AEW541 and NVP-ADW742, directed against IGF-1R kinase domain displayed potent 
activity in vitro and in vivo in fibrosarcomas, multiple myeloma, colorectal cancer and 
pancreatic cancer (García-Echeverría et al. 2004; Mitsiades et al. 2004; Höpfner et al. 2006; 
Moser et al. 2008). The concern with IGF-1R targeted therapy is the potential of impaired 
glucose metabolism - fortunately most studies observe no adverse side effects and no real 
difference in plasma glucose levels in in vitro and in vivo cancer models (García-Echeverría 
et al. 2004; Mitsiades et al. 2004). The long term effects of IGF-1R inhibition still need to be 
determined. Knockdown of IGF-1R in OSCC cell lines WHCO1 and WHCO6 resulted in an 
interesting phenotype, with a 50% reduction in IGF-1R level, elevated pEGFR and pERK1/2 
levels despite these cells growing similar to control cells. When EGFR was inhibited in these 
cells a 2-3 fold increase in sensitivity to AG1478 compared to control cells was observed. 
Recalling that our data suggested an IGF-1R/AKT negative feedback regulatory loop 
opposing EGFR/ERK1/2 activity in OSCC cells, this observation suggested that cells became 
more reliant on active EGFR when this feedback loop was disrupted. This is consistent with 
reports which observed that co-targeting EGFR and IGF-1R in other cancers led to increased 












knockdown cells were treated with cisplatin, doxorubicin and novel gold-based 
organometallic compounds (data not shown) no further increase in drug sensitivity was 
observed, which was consistent with a report that colorectal cancer cells showed no increased 
sensitivity to 5-fluorouracil or oxaliplatin combined with IGF-1R inhibition (Dallas et al. 
2009). This suggested that the increased sensitivity observed when co-targeting EGFR and 
IGF-1R in WHCO1 and WHCO6 OSCC cells was specific for these two receptors. 
 
The relevance of EGFR and IGF-1R receptor interaction in cancer biology is not clear but as 
these receptors are commonly overexpressed it suggests that cancer cells exploit multiple 
pathways to survive, since targeting of a single receptor is often n t sufficient to kill tumour 
cells. Our data suggests that in OSCC which overexpress EGFR and IGF-1R, targeting both 





























The role of CXCR2 in chemotaxis of immune cells (neutrophils, macrophages and 
leukocytes) and capillary formation in endothelial cells has been well documented and 
characterised (Raman et al. 2007; Waugh & Wilson 2008; Matsuo et al. 2009). Dysregulation 
of components of the chemokine pathway can result in chronic inflammation, which can lead 
to various disease states, including cancer (Raman et al. 2007). Evidence in the literature has 
linked CXCR2 expression with cancer, but its exact role in this disease is unclear. CXCR2 
overexpression in NIH 3T3 cells resulted in transformation in vitro and promoted tumour 
development and metastasis in nude mice (Burger et al. 2005). Elevated expression of 
CXCR2, which correlated with tumourigenesis, angiogenesis and metastasis, was reported in 
prostate, lung, melanoma and pancreatic cancer. CXCR2 was reported to be pro-
tumourogenic in melanoma, and its expression was found to correlate with melanoma stage, 
tumour aggression and metastasis (Singh et al. 2009) while in normal skin fibroblasts and 
benign lesions, CXCR2 expression correlated with oncogene induced senescence (Acosta et 
al. 2008; Acosta & Gil 2009; Matsuo et al. 2009; Singh et al. 2009; Yang et al. 2010). 
Although reports are contradictory regarding CXCR2 function in tumourogenesis or 
senescence, in vivo targeting of CXCR2 has highlighted its role in tumour proliferation, 
angiogenesis and metastasis. In pancreatic and skin carcinogenesis, inhibition of CXCR2 in 
vivo with either neutralising antibody or by CXCR2 knockdown resulted in significantly 
reduced tumour size and blood vessel density (Cataisson et al. 2009; Matsuo et al. 2009). 












wild-type mice displayed substantially reduced tumour growth and metastasis (Keane et al. 
2004). The reduced tumour volume, angiogenesis and metastasis observed when targeting 
CXCR2 in vivo was attributed to the involvement of CXCR2 in angiogenesis. A study 
performed in our laboratory found that CXCR2 and its ligands GROα and GROβ were 
overexpressed in OSCC tissue compared to adjacent normal epithelial tissue (Wang et al. 
2006; Wang et al. 2009). In this study we evaluated the potential of CXCR2 as a target in 































3.2 Results:  
3.2.1 CXCR2 expression and signal inhibition with anti-CXCR2 antibody or stable 
knockdown in OSCC cells  
We had previously shown in our laboratory that CXCR2 and its ligands GROα and β may 
play a role in the proliferation and survival of OSCC cells. This data suggested that CXCR2 
may serve as a potential therapeutic target for OSCC. Our first objective was to confirm the 
expression of CXCR2 in cultured OSCC cell lines. Protein was harvested from cultured 
OSCC cell lines, and subjected to western blot analysis using an antibody which recognizes 
total CXCR2. All OSCC cells, except KYSE 70, expressed CXCR2 by western blot analysis 
(Fig. 3.1). CXCR2 was detected as two distinct bands at a molecular weight of 48 kDa and 40 
kDa respectively. Others have reported that phosphorylation of CXCR2 results in degradation 
of the receptor which results in two bands being detected by western blot (Mueller et al., 
1997 and Schraufstatter et al., 1998). WHCO1 and WHCO6 cells were chosen as model cell 
lines as these cells have routinely been used in previous studies in our laboratory (Whibley et 



















Figure 3.1: CXCR2 expression in OSCC cell lines.  
OSCC cells were cultured to 60-70% confluency and protein was harvested. A total of 40ug of protein lysate 
from each cell line was separated by SDS-PAGE and transferred to nitrocellulose membrane. The membrane 
was probed with antibodies recognizing total CXCR2. β -tubulin was used as a loading control for all further 







To test the activity of CXCR2, cells were stimulated with GROβ which binds specifically to 
CXCR2. At the time of this study antibodies that specifically recognized phosphorylated 
CXCR2 were not available, and we thus measured AKT and ERK1/2 activity as these are 
known downstream targets of activated CXCR2 (Fan et al. 2003; Sai et al. 2006). WHCO1 
cells were cultured in 60mm dishes and serum starved for 1 hr. Following serum starvation 
cells were treated with 100ng/ml GROβ for ten min (Fig. 3.2A). GROβ treated cells 
displayed an increase in pERK1/2 and pAKT levels compared to untreated cells suggesting 
that CXCR2 was functional in our model system. To investigate basal CXCR2 activation, 
WHCO1 cells were incubated with 1ug/ml CXCR2 neutralising monoclonal antibody for one 
hr and pAKT and pERK1/2 levels were measured by western blotting (Fig. 3.2B). A 
substantial reduction in basal pERK1/2 levels was observed while pAKT levels were only 



























































Figure 3.2: Effect of Groβ and CXCR2 neutralising antibody on pAKT and pERK1/2 levels in WHCO1 
cells.  
WHCO1 cells were seeded at a density of 3 x 105 cells per 60 mm dish and stimulated with 100 ng/ml Groβ 
ligand for ten min (A) or treated with 1 µg/ml neutralising CXCR2 monoclonal antibody (Mab331) for 1 hour 
(B) and protein was harvested. A total of 40 µg of protein lysate from each cell line was separated by SDS-
PAGE and transferred to nitrocellulose membrane. The membrane was probed with antibodies recognizing 









The effect of neutralizing CXCR2 MAb on OSCC proliferation was tested in WHCO1 and 
WHCO6 cells. Cells were seeded at 1500 cells per well in triplicate in 96 well plates and 
proliferation was determined in the presence of 2 µg/ml CXCR2 neutralizing antibody 
supplemented every 24 hr over a period of 4 days. No significant decrease in proliferation 
was observed despite treating cells with 2 fold more neutralising antibody than is required to 
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Figure 3.3: Effect of CXCR2 Mab331 on WHCO1 and WHCO6 OSCC cell proliferation  
WHCO1 and WHCO6 OSCC cells were seeded at 1500 cells per well in a 96 well plate in triplicate. Cells were 
treated with 2 µg/ml neutralising CXCR2 monoclonal antibody supplemented every 24 hr for the indicated time 
periods. Cell proliferation was determined by MTT assay. The absorbance of WHCO1 and WHCO6 cells was 
determined using a plate reader and plotted as a line graph in Microsoft Excel®. Each point was performed in 




















































WHCO1 cell proliferation in the presence of CXCR2 Mab331  












Figure 3.4: CXCR2 mRNA expression in WHCO1 and WHCO6 Ctrl and CXCR2 shRNA cells. 
WHCO1 and WHCO6 Ctrl and CXCR2 shRNA cells were seeded at 3 x 105 cells per 60 mm dish and cultured 
overnight. RNA was extracted the following day and cDNA was synthesized and subjected to real-time PCR. 
Primers specific for CXCR2 was used to amplify CXCR2 and GUSB primers were used as a control. Relative 
expression of CXCR2 was calculated using the delta-delta CT method. Each point was performed in triplicate 










































































Considering that treatment with neutralising CXCR2 Mab had no effect on proliferation, even 
at a concentration sufficient to reduce pERK1/2 signalling, we used a CXCR2 knockdown 
system to further explore the role of CXCR2 in OSCC cells. WHCO1 and WHCO6 cells 
were infected with lentiviral particles containing CXCR2 shRNA or control shRNA, and 
pools of cells with greater than 95% GFP positivity (lentiviral vectors used contained GFP) 
were used for further studies. WHCO1 and WHCO6 CXCR2 knockdown cells were cultured 
and RNA and protein was harvested for real-time PCR and western blot analysis of CXCR2. 
The mRNA levels of CXCR2 were significantly reduced by >80% (p ≤ 0.0005) in WHCO1 






















Figure 3.5: CXCR2 protein expression in WHCO1 and WHCO6 Ctrl and CXCR2 shRNA cells 
WHCO1 and WHCO6 Ctrl and CXCR2 shRNA cells were seeded at 3 x 105 cells per 60 mm dish and allowed 
to settle overnight. Protein was harvested and 40 µg of each sample was separated by SDS-PAGE and 





































Analysis of CXCR2 protein levels in CXCR2 knockdown cells, by western blotting, revealed 
substantial reduction in CXCR2 levels (Fig. 3.5). The proliferation of WHCO1 and WHCO6 
CXCR2 knockdown cells compared to control cells was next determined. WHCO1 and 
WHCO6 control and CXCR2 knockdown cells were seeded in 96 well plates at 1500 cells 
per well and growth was measured by the MTT assay over the indicated time period. CXCR2 
knockdown cells grew at the same rate as control cells with no detectable differences in 
proliferation (Fig. 3.6), consistent with our previous results using the neutralising antibody. 
Our observation is also consistent with reports that inhibition of CXCR2 has no impact on 
cell growth under in vitro conditions (Mestas et al. 2005; Wislez et al. 2006; Cataisson et al. 































Figure 3.6:  Proliferation of WHCO1 and WHCO6 control and CXCR2 knockdown cells 
WHCO1 and WHCO6 control and CXCR2 knockdown cells were seeded at 1500 cells per well in triplicate in 
96 well plates and cultured for the indicated time periods. Cell proliferation was determined by means of MTT 
assay. The absorbance of WHCO1 and WHCO6 control and CXCR2 shRNA cells was determined using a plate 













Thus far our data suggested that inhibition of CXCR2 with a neutralizing antibody or CXCR2 
knockdown had no significant impact on cell proliferation. This was contradictory to our 
previous observation which demonstrated that knockdown of GROβ with shRNA was 
associated with a decrease in cell proliferation (Wang et al. 2006). Another strategy using 
CXCR2 inhibitor SB225002, was employed to determine the effect of CXCR2 inhibition on 
cell proliferation.  
 
3.2.2 Effect of CXCR2 inhibitor SB225002 in OSCC cells  
 
Previously we had shown that 200 nM SB225002 was capable of reducing cell proliferation 
by 50% (Wang et al. 2006). Here the IC50 for SB225002 of two normal fibroblast cells, DMB 
(skin) and WI38 (lung) and two OSCC cell lines, WHCO1 and WHCO6 was determined. 
Cells were plated at a density of 5000 cells per well in 96 well plates, treated with the 
indicated concentrations of SB225002 and the MTT assay was performed. The OSCC cells 
WHCO1 and WHCO6 showed IC50 values of 2.5 µM and 2.4 µM respectively (3.7C and D) 
while no IC50 value could be determined for the normal fibroblast cells, DMB and WI38 
since they appeared resistant to the effects of SB225002 (Figure 3.7A and B). The 
observation that CXCR2 inhibition had no effect on DMB and WI38 cell survival and 
proliferation is consistent with a recently published report (Acosta et al. 2008). The authors 
found that CXCR2 activates senescence in DMB fibroblasts which was alleviated when 
CXCR2 was knocked down or inhibited by SB225002 (Acosta et al. 2008). We observed that 
lower concentrations of SB225002 (0-10 µM) had no effect on DMB and WI38 
metabolism/viability after 48 hr while the increase in OD at the higher concentration of drug 
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The effect of 2 µM SB225002 on proliferation of OSCC cells was determined based on the 
IC50 values obtained earlier in Figure 3.7. WHCO1 and WHCO6 cells were seeded in 96 well 
plates and treated with 2 µM SB2205002 over the indicated time period (Fig. 3.8). SB225002 
treatment completely inhibited cell proliferation in WHCO1 and WHCO6 cells (p ≤ 0.0005), 
suggesting that CXCR2 activity was required for cell proliferation in these cells.  
Figure 3.7:  Drug sensitivity of OSCC and normal fibroblast cell lines to SB225002   
Normal skin fibroblast cells DMB (A) and normal lung fibroblasts WI38 (B) and WHCO1 and WHCO6 OSCC 
cells (C and D) were seeded at a density of 5000 cells per well in triplicate in 96 well plates. Cells were treated 
with a range of concentrations of SB225002 to determine the IC50 after 48 hr by the MTT assay. Absorbance 
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Figure 3.8:  Effect of SB225002 on WHCO1 and WHCO6 cell proliferation   
WHCO1 and WHCO6 OSCC cells were seeded at 1500 cells per well in triplicate in 96 well plates. The 
following day cells were treated with 2 µM SB225002 over the indicated time period and cell proliferation was 
measured by MTT assay. Absorbance was read with a multi-plate reader at 595 nm. Each point was performed 
in triplicate and error bars represent STDEV. (* p ≤ 0.0005) 
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Our results (Fig. 3.7 and 3.8) clearly indicated that SB225002 inhibited proliferation of 
WHCO1 and WHCO6 cells. We next determined the effect of SB225002 treatment on the 
cell cycle profile of cells to better understand the mechanism of action of this compound. 
WHCO1 and WHCO6 cells were seeded in 60 mm dishes in triplicate and treated with 2 µM 
SB225002 for 8, 24 and 48 hr. Cells were trypsinized, stained with propidium iodide and was 
analyzed by flow cytometry. A significant G2/M arrest was observed as early as 8 hr in cells 
treated with SB225002, with 64% of WHCO1 and 48% of WHCO6 cells (p ≤ 0.005), 
respectively, blocked in the G2/M phase, compared to untreated cells (14% for WHCO1 and 
13% for WHCO6) (Fig. 3.9). However this arrest was lost at the 24 hr and 48 hr time points. 
The loss of the G2/M arrest at the 24 hour and 48 hour point was associated with a substantial 
increase in the sub G1 population (p ≤ 0.005), suggesting that a significant proportion of cells 

































G2 14.38 63.63 13.05 13.02 7.23 13.04
S	   46.23 28.32 42.29 30.05 12.12 28.63
G1	   38.60 0.40 43.75 33.58 77.22 32.90






























G2 11.72 47.94 9.64 7.83 9.68 10.42
S	   49.82 42.44 46.73 29.56 14.50 32.66
G1	   37.16 0.00 42.42 39.69 72.58 32.21


















Figure 3.9: Cell cycle profile of OSCC cells treated with SB225002.  
WHCO1 and WHCO6 cells were seeded at a density of 3x105 cells per 60mm dish in triplicate and cultured for 
24 hr. The following day cells were treated with 2uM SB225002 for 8, 24 and 48 hr. Cells were processed for 
flow cytometry and stained with propidium iodide. The cell cycle profile of cells was analysed on a FACS 
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The cell cycle is tightly regulated by cyclins (cyclin A, cyclin B and cyclin D); cyclin 
dependent kinases (CDK4, CDK6, CDK2) and cell cycle check point proteins including p21, 
p27 and p53 (Stark & Taylor 2006). The G2/M arrest observed in cells treated with 
SB225002 at the 8 hr time point may be associated with an alteration in cyclin protein levels 
that can be detected by western blot. WHCO1 and WHCO6 cells were plated in 60 mm 
dishes and treated with SB225002 for 4 and 8 hr respectively. Protein was harvested, 
subjected to western blotting and probed with specific antibodies for p27 and cyclin B. 
Cyclin B is essential for orchestrating the progression from G2 to mitosis while p27 is one of 
the important cell cycle inhibitors of G2/M (Mukherjee et al., 2010). Consistent with the 
G2/M arrest observed in Figure 3.9, cyclin B levels were increased at the 4 and 8 hour time 
points (Fig 3.10). No change was observed for p27 suggesting no involvement with the cell 


































The increase in the sub G1 population observed in the cell cycle analysis experiments (Fig. 
3.9) at the later time points following the G2/M arrest suggested that cells were undergoing 
cell death. To further understand this observation cells were seeded in 60 mm dishes, treated 
with 2.5 µM SB225002 and protein was harvested. Western blot analysis was conducted 
using antibodies specific to pH2AX and PARP. When double strand DNA breaks occur 
histone 2AX becomes phosphorylated. These double-strand DNA breaks can indirectly be 
detected by western blot analysis as an increase in pH2AX positivity. A significant increase 
Figure 3.10:  Effect of SB225002 on cell cycle proteins cyclinB and p27 in OSCC cells 
WHCO1 and WHCO6 cells were plated in 60 mm dishes at 3 x 105 cells. Cells were treated with 2.5 µM 
SB225002 for the indicated times (in hr) and protein was harvested. A total of 40 µg of each sample was 
separated by SDS-PAGE and transferred to nitrocellulose membrane. The membrane was probed with antibody 
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in DNA damage was observed at the later time points in cells treated with 2.5 µM SB225002 
compared to untreated cells (Fig 3.11) and apoptosis observed as cleaved PARP was evident 
















Figure 3.11:  Effect of SB225002 on DNA damage and apoptosis in OSCC cells  
WHCO1 and WHCO6 cells were plated in 60 mm dishes at 3 x 105 cells. Cells were treated with 2.5 µM 
SB225002 for the indicated times and protein was harvested. A total of 40 µg of each sample was separated by 
SDS-PAGE and transferred to nitrocellulose membrane. The membrane was probed with antibodies specific for 






























Considering that the effect of SB225002 is mediated by the CXCR2 receptor, we wanted to 
determine whether the CXCR2 knockdown cells displayed resistance to SB225002. CXCR2 
knockdown cells were plated at 1500 cells per well in 96well plates and treated with 1.5 µM 
SB225002 over a period of days. WHCO1 and WHCO6 CXCR2 knockdown cells treated 
with 1.5 µM SB225002 grew similar to untreated CXCR2 knockdown and control cells 
despite being challenged with drug (Fig 3.12). Proliferation of control cells, which expressed 
CXCR2, was significantly reduced compared to  WHCO1 and WHCO6 CXCR2 shRNA cells 











































Proliferation of WHCO1 Ctrl and CXCR2 shRNA cells in response to SB225002  
Figure 3.12:  Effect of SB225002 on control and CXCR2 knockdown cell proliferation 
WHCO1 and WHCO6 control and CXCR2 knockdown cells were seeded at 1500 cells per well in triplicate in 
96 well plate. Cells were treated with 1.5 µM SB225002 and proliferation was monitored by MTT assay over 
the indicated times. Absorbance was read with a multi-plate reader at 595 nm. Each point was performed in 
triplicate and error bars represent STDEV. (* p ≤ 0.005)	  
*	   *	  
*	   *	  
*	  
*	  
Proliferation of WHCO6 Ctrl and CXCR2 shRNA cells in response to SB225002  














We have previously shown that SB225002 induces a G2/M arrest at the 8 hr time point in 
wild-type WHCO1 and WHCO6 cells. We wanted to investigate the effect of SB225002 on 
the cell cycle of CXCR2 knockdown cells at a density of 3 x 105 cells per dish, followed by 
treatment with 2 µM SB225002 for 8 hr. Cells were harvested, stained with propidium iodide 
and their cell cycle profile was determined. We observed a G2/M arrest in the control cells 
treated with SB225002 (p ≤ 0.0005), however, CXCR2 knockdown cells displayed no G2/M 
arrest suggesting that CXCR2 was involved with mediating the SB225002-induced G2/M 
arrest in cells expressing CXCR2  (Fig. 3.13). Our data suggest that CXCR2 could be a good 










































G2 2.94 69.61 0.81 12.34
S	   61.01 19.32 59.59 26.04
G1	   34.76 10.72 39.15 56.72
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G2 4.56 60.50 6.72 0.40
S	   43.48 6.24 16.15 28.58
G1	   51.24 16.47 76.37 69.80








WHCO6	  Ctrl	  &	  CXCR2	  shRNA	  Cell	  Cycle	  with	  2.5uM	  SB225002
Figure 3.13: Cell cycle profile of CXCR2 knockdown cells treated with SB225002.  
WHCO1 and WHCO6 control and CXCR2 knockdown cells were seeded at a density of 3 x 105 cells per 60 mm 
dish in triplicate and left to settle overnight. The following day cells were treated with 2.5 µM SB225002 for 8 
hr. Cells were processed for FACS analysis and stained with propidium iodide. The cell cycle profile of cells 
was analysed on a FACS Callibur machine. Each point was performed in triplicate and error bars represent 





































Our original observations (Wang et al. 2006) suggested that CXCR2 signalling contributed to 
survival and proliferation in OSCC cells, since a knockdown of GROβ in these cells, or 
treatment with an inhibitor of CXCR2 SB225002, reduced cell proliferation by approximately 
50%.  These observations were consistent with reports that described functional 
CXCR2/ligand signalling loops in melanoma cell lines, and that these contributed to 
proliferation (Singh et al. 2009; Yang et al. 2010).  The involvement of CXCR2 in OSCC 
proliferation and survival suggested that these receptors may represent feasible targets in the 
treatment of OSCC, an attractive option considering our observation that CXCR2 was 
overexpressed in 88% of primary OSCC tissue examined by IHC (Wang et al. 2006). 
In this study we demonstrated that most OSCC cell lines examined (8/9) express CXCR2 that 
was functional, based on the phosphorylation of AKT and ERK1/2 in response to GROβ 
treatment.  Furthermore, treatment of cells with a neutralizing antibody to CXCR2, resulted 
in decreased basal pAKT and pERK levels, suggesting that CXCR2 signalling contributed to 
basal pAKT and pERK levels in OSCC cell lines.  Signalling from CXCR2 to the 
MAPK/ERK1/2 and PI3K/AKT pathways is important for the activation of genes involved 
with cell cycle progression and proteins involved with protein translation and cell 
polarization respectively (Yang et al. 1999; Zhao et al. 2004; Sai et al. 2006; Chapman et al. 
2009). Contrary to our previous observation, blockade of CXCR2 using two different 
approaches - either neutralizing antibodies to CXCR2, or CXCR2 knockdown with shRNA, 
had no effect on cell proliferation. This result was observed in two OSCC cell lines, 
suggesting that we were not observing cell line specific artefacts.  Although the level of 












higher than that required to reduce pAKT and pERK1/2 levels by >50% (Fig. 3.2), and even 
if antibody levels were supplemented every 24 hr, it is still possible that this may not have 
been sufficient to block CXCR2 activity.  Although numerous reports show that inhibition of 
CXCR2 in vivo with neutralizing antibody results in decreased angiogenesis and ultimately 
reduced tumour volume - consistent with our data, no observable changes in cell proliferation 
have been reported when targeting CXCR2 in vitro with an anti-CXCR2 antibody (Karl et al., 
2005; Keane, Belperio, Ying Y Xue, Marie D Burdick, & Robert M Strieter, 2004; Matsuo et 
al., 2009).  However, it is very difficult to rationalize the CXCR2 knockdown experiments.  
Our results convincingly demonstrates a substantial reduction in CXCR2 mRNA levels in 
both WHCO1 and WHCO6 cell lines (>95%), and also shows a substantial reduction in 
CXCR2 protein levels.  Despite this evident depletion of CXCR2 activity, the CXCR2 
shRNA expressing cells show proliferation values similar to control cells (for both cell lines).  
These results are consistent with our findings showing no effect of neutralising antibody on 
proliferation, and suggest that the absence of CXCR2 does not reduce cell proliferation or 
survival in OSCC cells. This is in contrast to results obtained previously in our laboratory 
showing that GROβ knockdown resulted in a 50% reduction in cell proliferation (Wang et al. 
2006). The two experimental systems are very different. In the earlier system, knockdown of 
GROβ was presumably associated with unoccupied CXCR2 located on the plasma 
membrane, bound to accessory proteins, whereas in the current experimental system, no, or 
very little CXCR2 was located at the plasma membrane.  Altered CXCR2 signalling to 
arrestins and adaptor-protein 2, crucial for receptor desensitization and controlled signalling, 
can result in apoptosis of cells (Revankar et al. 2004; Wagener et al. 2009). This may explain 
the reduced proliferation in the GROβ knockdown cells, but not CXCR2 knockdown OSCC 
cells, as CXCR2 signalling to arrestins may have been defective. It is also possible that the 












less likely since two different sequences were used, with similar results observed. Maybe 
some of these differences underlie the contradictory effects of these two approaches on cell 
proliferation, but they require further investigation before this conundrum can be resolved.   
We have consistently demonstrated that the CXCR2 inhibitor, SB225002, strongly inhibits 
OSCC cell proliferation, with an IC50 of about 2 µM, whereas the proliferation of fibroblasts 
was unaffected by SB225002, even at concentrations of 100 – 200 µM.  Likewise, Acosta et 
al., (2008) had observed that normal skin fibroblast cells (DMB cells) were insensitive to 
SB225002 and that inhibition of CXCR2 in these cells increased their proliferative ability. 
Our observation that inhibition of CXCR2 in OSCC cells results in cell death compared to 
normal cells, which are insensitive to CXCR2 inhibitor is consistent with reports that CXCR2 
has opposing roles in cancers compared to normal cells (Acosta et al. 2008;  Acosta & Gil 
2009). CXCR2 is suggested to activate proliferation, angiogenesis and metastasis in cancer 
cells while in normal cells it can activate senescence (Acosta & Gil 2009; Cataisson et al. 
2009; Matsuo et al. 2009; Singh et al. 2009). 
 
Further investigation of the toxic effect of SB225002 in OSCC cells, revealed that relatively 
low concentrations of this CXCR2 inhibitor caused a strong G2/M block at 8 hr after 
treatment, and that this was associated with elevated levels of cyclin B. G2/M arrest in cells is 
frequently associated with defects in DNA repair mechanisms, aberrant spindle attachment 
and altered polarization of spindle microtubules (Mukherjee et al. 2010). A review of the cell 
cycle by Stark and Taylor (2006) suggested p53 involvement in maintaining the G2/M arrest 
in cells treated with radiation (Stark & Taylor 2006). The G2/M block observed at the 8 hour 
point after SB225002 treatment, was not observed at the 24 hour and 48 hour point (post 
SB225002 treatment), but substantial amounts of sub G1 debris was observed. Indeed, PARP 












were due to apoptosis, suggesting that cells were either undergoing apoptosis directly in the 
G2/M phase, or that they first exited G2/M, then undergo apoptosis.     
Seeing that the G2/M arrest and apoptosis induced by SB225002 was dependent on CXCR2 
presence but knockdown of CXCR2 or inhibition by neutralizing antibody had no effect on 
OSCC cell biology, it suggests to us that the drug when bound to CXCR2 results in aberrant 
receptor function. When neutralizing antibody is bound to receptor, receptor levels are 
decreased as a result of internalization and degradation (Rowinsky 2004), while in CXCR2 
knockdown cells only low levels of receptor are present. We hypothesise that the CXCR2 
knockdown cells and cells treated with neutralizing antibody are thus similar in this regards, 
hence no effect on proliferation was observed. When cells were treated with SB225002, it is 
possible that this compound interferes with the normal processing of CXCR2, leading to 
apoptosis. CXCR2 could be trapped at the cell membrane when bound to SB225002 as 
reported by Acosta et al. (2008). Localization of CXCR2 bound to SB225002 at the cell 
membrane may have resulted in association of arrestins with CXCR2 which has been 
reported to activate apoptosis when its function is impaired (Revankar et al. 2004; Wagener 
et al. 2009). Alternatively, if CXCR2 bound to inhibitor was internalized, this could result in 
accumulation of drug in intracellular compartments or endosomes resulting in deregulated 
endosomal pathways leading to cell death.  
 Our data suggests that CXCR2 is overexpressed in OSCC cell lines and OSCC patient tissue 
compared to normal cells and adjacent tissue (Wang et al. 2006). Furthermore CXCR2 
inhibition with inhibitor results in apoptosis of OSCC cells that display receptors, however, 
OSCC cells which lack CXCR2 were insensitive to inhibitor. This highlights the importance 
of CXCR2 as a potential therapeutic target in OSCC.  Normal cells which express little to no 












novel, and in fact, the induction of apoptosis by SB225002 has only very recently been 
observed in head and neck cancer cells (Romanini et al. 2011). There is thus precedent for the 
observation that SB225002, can kill cancer cells (albeit very recent evidence), and strongly 
supports our case that SB225002, could be a very useful drug in our limited arsenal of 

































OSCC currently presents a significant health burden in many developing countries and will 
continue to do so for the foreseeable future.  We could reduce the morbidity and mortality 
associated with this disease if better therapeutic options for these patients could be developed.  
Of course, the discovery and implementation of more effective early diagnostic measures 
could be equally, if not more effective in this regard, and it is important that research in this 
area continue unabated.   
 
This project, however, focussed on the identification and characterisation of potential 
therapeutic targets in OSCC.  Here we demonstrated that OSCC cells show increased 
sensitivity to AG1478 (the EGFR inhibitors) when IGF-1R is blocked, suggesting that the 
simultaneous targeting of EGFR and IGF-1R may be a promising strategy to follow in OSCC 
patients. In this project, simultaneous targeting of these two receptors was associated with 
increased apoptosis.  These results seem very promising and they suggest a course of action 
that could be considered.  It would be interesting to test some of the newer specific IGF-1R 
inhibitors, and determine if the simultaneous targeting of IGF-1R and EGFR in parental 
OSCC cell lines kill these cancer cells more efficiently than separate treatment.  If the 
simultaneous targeting of EGFR and IGF-1R in cultured OSCC cells lead to the more 
effective induction of apoptosis, the next step should be to test the effect of these compounds, 
individually or in combination on the growth of OSCC human xenografts in a nude mouse 
model.  A successful study using xenografts in a nude mouse model would be a very strong 












positivity for both EGFR and IGF-1R.  This approach seems reasonable considering the 
clinical implications of the results reported here for EGFR and IGF-1R. 
 
However, the results of this study also raise interesting questions about the biology of EGFR 
and IGF-1R function.  The knockdown of IGF-1R show that reduced IGF-1R levels on the 
plasma membrane of OSCC cell lines, is associated with elevated levels of pEGFR, and that 
this result is not mediated through AKT, but possibly directly through IGF-1R (considering 
the effects of the AKT inhibitor).  It would be very interesting to determine how this 
phenomenon is mediated.  Furthermore, the functional significance of the transient activation 
of IGF-1R observed in response to EGF treatment is also an interesting observation that could 
be investigated further. 
 
As mentioned before, it is difficult to rationalise the results observed earlier in our laboratory 
where knockdown of GROα and GROβ was associated with a reduction in cell proliferation 
in OSCC cell lines, with the present results which indicate that a CXCR2 neutralising 
antibody, and CXCR2 knockdown, both had no measurable effect on cell proliferation.  
These divergent observations require further investigation.   
 
Our results observed for CXCR2 also have potentially important clinical implications.  The 
induction of apoptosis in OSCC cells by relatively low levels of SB225002 (IC50 of 2 – 3 
µM), combined with the observation that 5 – 10 fold this concentration had no inhibitory 
effect on fibroblast proliferation, suggest that SB225002, should be tested in a OSCC 
xenograft model in nude mice.  A positive response in a xenograft mouse model should be 
followed by clinical trials of SB225002 in OSCC patients positive for CXCR2, to determine 












defects in development (Keane et al. 2004; Svensson et al. 2008), suggesting that this 
therapeutic approach may have minimal side effects.   
 
Although our results here show that treatment of OSCC cell lines with SB225002 was 
associated with an early cell cycle disruption (G2/M block at 8 hr), DNA damage (H2AX 
phosphorylation) and the induction of apoptosis (PARP cleavage), it would be interesting to 
determine how SB225002 triggers this response in OSCC cells, and not fibroblasts for 
example.  Is ROS production involved in this process, and is this associated with the DNA 
damage observed?  These questions are currently being explored in our laboratory, so that we 
can understand how the effects of SB225002 are mediated in OSCC cells. 
 
We highlighted the potential of three receptors as therapeutic targets for the management of 
OSCC with novel findings including a negative regulatory IGF-1R/AKT loop, increased cell 
death when specifically targeting EGFR and IGF-1R simultaneously and specific killing of 
CXCR2 positive cancer cells verses CXCR2 negative or CXCR2 expressing normal 
fibroblast cells. Our data should be considered for further in vivo evaluation as we have 




















Materials and Methods:  
5.1.i Cell culture 
Oesophageal squamous cell carcinoma (OSCC) cell lines, WHCO1, WHCO5 and WHCO6 
were obtained as a generous gift from Dr Veale (Veale and Thornley 1984) and KYSE30, 
KYSE70, KYSE150, KYSE180, KYSE410 and KYSE450 were obtained from Dr Shimido –
Japan and purchased from the DSMZ cell bank. Normal skin fibroblast cell lines, FG0 and 
DMB were obtained as a generous gift from Dr A. D. Marais (Groote Schuur Hospital, Cape 
Town) and normal lung fibroblast cell line, WI38, were purchased from the American Type 
Culture Collection (ATCC) (Rockville, MD, USA). All the above cell lines were cultured at 
37°C in a humidified atmosphere of 5% CO2 and 95% air in Dulbecco’s modified Eagle 
medium (DMEM) containing 10% heat inactivated foetal calf serum, penicillin (100U/ml) 
and streptomycin (100 µg/ml). HEK293T cells (Invitrogen) were cultured at 37°C in a 
humidified atmosphere of 5% CO2 and 95% air in DMEM containing 10% heat inactivated 
foetal calf serum (Gibco), 0.1 mM MEM Non-Essential Amino Acids (Sigma), 2 mM L-
glutamine, penicillin (100U/ml) (Gibco), streptomycin (100 µg/ml) (Gibco), and 500µg/ml 
Geneticin (Sigma).  
 
5.1.ii Thawing Cells 
Culture medium was pre-warmed in a 37°C water-bath and 3 ml of pre-warmed media was 
added to a 60 mm dish. Cells were collected from liquid nitrogen tanks and thawed in a 37°C 
water-bath. Once cells were thawed the cells were transferred to a 10ml tube containing 3 ml 












removed, the cell pellet was resuspended in 1 ml of media and the cell suspension was added 
to the 60 mm dish.  Cells were placed in the 37°C incubator and were cultured for further 
experiments. 
 
5.1.iii Freezing Cells 
Cells were grown to 80% confluency, medium was removed and the dish was rinsed with 2 
ml of warm trypsin/EDTA (Difco). Another 2 ml of trypsin was added and incubated with 
cells for 1-2 min. Following incubation with trypsin/EDTA, cells were aspirated and then 
transferred to a 10 ml tube containing 4 ml of media. Cells were centrifuged at 1000 rpm for 
5 min, the supernatant was removed and the cell pellet was resuspended in a total of 5 ml of 
media. An aliquot of the cell suspension (10 µl) was counted by means of a haemocytometer 
to determine cell number. Medium, foetal calf serum and DMSO was added to the cell 
suspension so that the final concentration of cells per ml was 1x106, foetal calf serum 20%, 
DMSO 10%. One ml aliquots of cells were added to cryotubes and placed at -80oC for 2 days 
and then transferred to liquid nitrogen for long term storage.  
 
5.2 Protein Extraction and Processing 
Cells were seeded at a density of 3 x 105 cells per 60 mm and left overnight to settle. 24 hr 
later, cells were treated with various agents as indicated: EGF (Sigma); IGF-1 (Sigma); 
SB225002 (TOCRIS Bioscience); AG1478 (CalBiochem); cisplatin (TOCRIS Bioscience); 
AKT VIII trifluoroacetate salt (Sigma); doxorubicin (Sigma) at the indicated concentrations 
for the indicated time periods and protein was harvested. Media was collected from cells, 
followed by 2 washes with 2 ml of 1 x PBS which was also collected and this was centrifuged 












cells (60-100 µl) and cells were scraped using a cell scraper. Cell protein was then collected 
in eppendorf tubes. Media was removed from the 12 ml tubes containing a cell pellet 
obtained from the floating cells. The pellet was resuspended in Ripa buffer and the indicated 
additives and transferred to the corresponding eppendorf tube. Protein concentration was 
determined using the bicinchoninic acid (BCA) Protein Assay kit (Pierce, Thermo Scientific) 
as described by the manufacturers and then stored at -80oC. Protein (20 – 40 µg per sample) 
was prepared for SDS-PAGE by adding loading dye and heating samples at 85oC for 5 min, 
followed by loading samples on 10% SDS poly-acrylamide gels.  
 
5.3 Immunoprecipitation  
Cells were seeded in 100 mm dishes at a density of 1x106 cells. Protein was harvested in 
RIPA buffer as described above and quantified using the BCA kit. Protein (300 µg) was 
incubated with 2 µg EGFR antibody overnight at 4oC on a circular rotor. The next day 50 µl 
of protein-A agarose beads (Calbiochem) was added to each sample and incubated for 4 hr 
with agitation on a circular rotor at 4oC. Samples were centrifuged at 12000 rpm for 5 min, 
the supernatant removed and the pelleted beads were washed three times with 300 µl 1xPBS. 
After the final centrifugation PBS was removed so that a final volume of 25 µl remained, 6 µl 
of 5 x loading dye was added to samples, which were then heated at 85oC for 5 min and 
subjected immediately to Western blotting using 10% SDS-PAGE gels.  
 
5.4 Western Blot Analysis 
Ten or twelve percent SDS-PAGE gels were cast in either 1 mm or 1.5 mm glass plates using 
the BioRad Western blotting system. Resolving and stacking gel solutions were prepared as 












plates, water was added and this was allowed to set. Protein samples were prepared by 
thawing the samples on ice, determining the amount of sample required for 20-40 µg, and 
adding the appropriate amount of 5 x loading dye the prepared samples were heated to 85oC 
for 5 min and subjected to a pulse spin for 20 sec. The water was poured off the resolving gel, 
the stacking gel was added on top of the resolving gel and a 10 or 15 well comb was inserted. 









Stacking Gel Solution (5%) 1.5 mm gel 1 mm gel 
Stacking buffer 1.5 ml 750 µl 
Acrylamide 1 ml 500 µl 
dH2O 3.5 ml 1.75 ml 
10% APS 60 µl 30 µl 
TEMED 6 µl 3 µl 
 
Resolving Gel Solution 10%  
(1.5 mm gel) 
12%  
(1.5 mm gel) 
10%  
(1 mm gel) 
12%  
(1 mm gel) 
Resolving Buffer 3 ml 3 ml 2 ml 2 ml 
Acrylamide  3 ml 3.75 ml  2 ml 2.75 ml  
dH2O 3 ml 2.25 ml 2 ml 1.25 ml 
10% APS 150 µl 150 µl 100 µl 100 µl 












Protein was loaded alongside a protein ladder (Fermentas Spectra Multicolor Broad Range 
Protein ladder) for sizing and gels were electrophoresed at 150 V for 1 hr and 15 min. 
Following electrophoresis, proteins were transferred onto nitrocellulose membrane 
(Amersham Hybond ECL). An ice pack was placed in the tank which was subsequently filled 
with 1x transfer buffer. Protein transfer was carried out at 100 V for 90 min. Membranes 
were subsequently washed with 1x TBST and blocked for one hour in 5% non-fat powder 
milk made with 1x TBST. The blocking solution was removed, primary antibody was added 
(see Table 3 for concentrations) and membranes were incubated overnight at 4oC with 
shaking. The next day membranes were washed 3 x 5 min with 1x TBST and incubated with 
secondary antibody for 1hour at room temperature with shaking (see Table 3 for 
concentrations).  
Following this, membranes were washed 3 x 5 min with 1x TBST, placed on transparency 
film, incubated with chemiluminescence detection reagent (see table 3) and exposed to X-ray 
























and Cat no. 
1° Ab Conditions 
 




pEGFR (Tyr 1173) 




1:2000 2.5% BSA 
DαG Pierce Super Signal 
EGFR 
Santa Cruz  
sc-03 1:1000  2.5% Milk 
1:5000 5% Milk 




1:1000  2.5% 
Milk-BSA/5% BSA 






 1:1000  5% Milk 
1:5000  5% Milk 
GαR Biorad Super Signal 
pAKT (Ser 473) 
Cell Signalling 
9271 1:1000  5% BSA 






9272 1:1000  5% BSA 




pERK 1/2 (Thr 202/Tyr 
204) 
Cell Signalling 
9106 1:1000  1% BSA 






 sc-154 1:1000  1% Milk 
1:5000  2.5 % Milk 
GαR Biorad Super Signal 
β-Tubulin 




1:5000  5% Milk 
GαR Biorad Super Signal 
Cleaved-PARP  
Santa Cruz 
 1:2000  5% Milk 
1:5000  5% Milk 






1:4000 2.5% BSA 




1:1000 2.5% Milk 
 







1:1000 2.5% Milk 
 









1:5000  2.5 % Milk 












 M0800 1:5000  TBST 
1:5000  5% Milk 
GαR Biorad Super Signal 
 
 
5.5 RNA Extraction  
Cells were washed twice with 2 ml cold PBS and 600 µl per 60 mm dish or 1 ml per 100 mm 
dish of QIAzol (Qiagen) was added. Cells were incubated at RT for 5 min before being 
scraped off the dish and transferred to 1.5 ml eppendorf tubes and 0.2 ml of chloroform per 1 
ml of QIAzol used was added. Tubes were inverted for 15 sec and incubated on ice for 10 












aqueous phase was transferred to a clean 1.5 ml eppendorf tube and 0.5 ml of isopropanol per 
1 ml of QIAzol was added and RNA was precipitated overnight at -20oC. Samples were again 
centrifuged at 8000 rpm for 30 min at 4oC. The supernatant was removed and the resulting 
pellet was washed in 1 ml 75% ethanol per 1 ml of QIAzol. Samples were subjected to 
centrifugation at 8000 rpm for 20 min at 4oC. The supernatant was discarded and the pellet 
air-dried and then resuspended in 30 µl of DEPC water. RNA concentration was determined 
with a nano-drop (Thermo Scientific) and the integrity was determined by running 2 µg of 
RNA on a 1.5% agarose formaldehyde gel at 60 V for 45 min.  
 
5.6 cDNA synthesis 
cDNA was synthesized by taking 2 µg of RNA making it up to 8 µl with DEPC H2O and 
adding 1 µl of Oligo-dT primer (Promega). This was incubated at 70oC for 10 min followed 
by a pulse spin and immediately placing the mix on ice. cDNA was synthesized in a reaction 
containing 1 x first strand buffer,  2 mM MgCl2 (Promega), 1 mM dNTPs (Promega), 40 U 
RNasin (Promega), 1 µl reverse transcriptase (RT) (Promega) and 1.4 µl DEPC H2O. 11 µl of 
the above master mix was added to each tube and placed in a PCR machine set at 42oC for 2 
hr followed by 70oC for 10 min. cDNA was aliquotted and stored at -80oC.  
 
5.7 Quantitative real-time RT-PCR (qRT PCR) 
Gene-specific primer sequences are shown in Table 4. Primers were synthesised by UCT 
oligonucleotides synthesis facility, and 20 µM stocks for each primer were prepared. For one 
realtime PCR reaction 6.5 µl of distilled water, 9.5 µl of SyBrgreen Fast PCR reaction mix 












of cDNA was aliquotted into a PCR fast reaction tube (Applied Biosystems). All reactions for 
the target gene and housekeeping gene were performed in triplicate. Tubes were placed in a 
Realt-Time PCR machine (Applied Biosystems) and subjected to 1 cycle of 95oC for 3 min to 
activate the enzyme, followed by 40 cycles of 95oC for 1 second (denaturation) and 55oC for 
20 sec (annealing and extension). Melt curve was performed for analysis of PCR product 
melt profiles, to ensure the specificity of the reactions 
 
Table 4: Sequences of primers used for real-time RT-PCR 
Gene Sequence PCR product 
size (bp) 
Ta (°C) 
CXCR2 Forward 5’ CTCCAATAACAGCAGGTCAC 3’ 
279 55 
CXCR2 Reverse 5’ GGCTCAGCAGGAATACCA 3’ 
GusB Forward 5’ CTCATTTGGAATTTTGCCGATT 
3’ 
81 55 





5.8 siRNA Transfection: 
Cells were seeded at a density of 1.5 x 105 cells per 35 mm dish or 3 x 105 cells per 60 mm 
dish and left overnight in 37oC incubator to settle. The following day the transfection cocktail 












Transfection cocktail per:                   35 mm dish 60 mm dish  
Serum and pen/strep free DMEM        50 µl      114 µl 
Transfectin (BioRad)       0.625 µl     1.4 µl 
Incubate at room temperature for 5 min   
siRNA (control or EGFR) (Santa Cruz) (stock 10 µM)       2 µl     4.57 µl 
Incubate at room temperature for 20 min 
 
Media was removed from cells and replaced with 1 ml of complete DMEM. siRNA 
transfection cocktail was added dropwise to cells and incubated for 5-6  hr with cells. The 
transfection mix was then removed from cells and replaced with 2 ml of fresh media for at 
least 24 hr. Protein was harvested and analysed to determine the extent of knockdown. 
 
5.9 MTT Assay 
Cells were seeded in 96 well plates at a density of 1.5 x 103 cells per well in triplicate in 90 µl 
of media and left overnight in, 5% CO2, 37oC humidified incubators. The following day 10 µl 
of drug at 10 x the desired concentration, diluted in complete DMEM was added to each well. 
Cells were treated with a range of different concentrations of drug. Following a 48 hr 
incubation with drug 10 µl of sterile 5 mg/ml MTT [3-(4,5-Dimethylthiazol-z-yl)-2,5-
diphenyltetrazolium bromide] in PBS was added to each well and incubated with cells for 4  
hr followed by the addition of 100 µl of solubilisation solution (10% SDS, 10 mM HCl) 
which was incubated with cells for 16  hr. The following day of the OD of each well at 595 
nm was determined using a microtiter plate reader (Beckman) and results were analyzed 













5.10 Fluorescent Activated Cell Sorting (FACS)  
Cells were seeded at a density of 3 x 105 cells per 60 mm dish and incubated overnight at 
37oC. The following day cells were treated as described in specific figures. Cells were then 
harvested by collecting media in 12 ml tubes, rinsed with 2 ml of trypsin which was also 
collected. A further 2 ml of trypsin was added to cells and left for 3 min after which cells 
were trypsinized and collected in the 12 ml tubes corresponding to the appropriate sample. 
Tubes were centrifuged at 1000 rpm for 5 min and the supernatant was removed. Cells were 
then resuspended in 2 ml of complete DMEM, counted and finally 8 ml of absolute ethanol 
was added to fix cells. Samples were stored at -20oC for a period of 24 hr to a maximum of 2 
weeks. On the day of acquisition cells were centrifuged at 1000 rpm for 5 min. The 
supernatant was discarded and the cell pellet was rinsed and resuspended in 1 ml 1 x PBS 
followed by another round of centrifugation at 1000 rpm for 5 min and resuspension in 1 ml 
of 1x PBS. A total of 3 x 105 cells were aliquoted into 1.5 ml eppendorf tubes, centrifuged at 
1000 rpm for 5 min. After the supernatant was discarded, cells were resuspended in 50 µg/ml 
RNAse A in 1 x PBS to a final volume of 0.2 ml RNAse A per 1x106 cells and incubated at 
37oC for 15 min. Cells were then stained 20 min before FACS acquisition with 300 µl 
staining solution per 3 x 105 cells (0.1% Triton X-100, 2 mM MgCl2, 100mM NaCl, 10mM 
PIPES pH6.8 and 10 µg/ml propidium iodide) and cell cycle profiles were analysed using a 

















5.11 Lentiviral production for stable knockdown of IGF-1R and CXCR2 
 
A total of 2 x 106 HEK293T cells were cultured in DMEM media containing 10% heat 
inactivated foetal calf serum, 1% L-Glutamine (Sigma), 1% Non-essential amino acids 
(Sigma) (penicillin and streptomycin free) in 75 cm2 tissue culture flasks.  Once cells reached 
~80% confluency, they were transfected with 3 plasmids encoding parts of the lentivirus and 
target gene to be silenced. Transfection cocktail mix was prepared as follows: 8250ng pWPI 
transfer plasmid (Addgene); 3900ng psPAX2 packaging plasmid (Addgene); and 1300ng 
pMD2.G envelope plasmid (Addgene). Plasmids were equilibrated to a final volume of 105 
µl with serum-free OPTI-MEM  
To a separate tube, 33.5 µl FuGENE HD was added to 386.5ul of serum-free OPTI-MEM. 
(do not allow the FuGENE to come into contact with the walls of the tube) The solution was 
mixed by gently flicking the tube and incubated for 5 min at room temperature.  
The plasmid cocktail mix was added to the FuGENE HD serum-free OPTI-MEM mix 
dropwise. The plasmid and FuGENE cocktail was mixed by swirling or gently flicking the 
tube and was incubated for 30 min at room temperature.  
Finally, the transfection cocktail was added dropwise to the HEK293T cells in the flask 
which was swirled to ensure even mixing (Do not mix transfection and cells too roughly as 
cells may be dislodged). Cells were incubated for 12-15 hr with transfection cocktail at 37oC 
in an incubator. The following day medium containing the transfection cocktail was removed 
and 8 ml of fresh medium was added, cells were further incubated for 24 hr. Medium was 
transferred from HEK293T cells with disposable 10ml pipettes to 50ml polystyrene tubes and 
centrifuged at 1000 rpm for 5 min to pellet cell debris. A further 8 ml of fresh medium was 












was aspirated with a syringe through a 0.45 µM filter (MILLEX-HV, PVDF, MILLIPORE) and 
4ml aliquots were made in 12ml polystyrene tubes and stored at -80oC for later use. Target 
cell lines, WHCO1 and WHCO6 cell were seeded at a density of 5 x 105 cells per 60 mm dish 
and infected with the 4 ml aliquots of lentiviral particles containing Ctrl, CXCR2 or IGF-1R 
shRNA. Cells were incubated with lentivirus overnight and the next day media was changed 
and cells further cultured for protein, mRNA and to make cell stocks. IGF-1R shRNA cells 
were sorted based on GFP positivity while CXCR2 shRNA expressing cells were infected 
twice with viral particles. WHCO1 and WHCO6 control and IGF-1R shRNA cells were 
generated by a previous PhD student and CXCR2 shRNA cells were generated with the 
assistance of a fellow PhD student. A published CXCR2 shRNA sequence, described by 






















Figure 1: Cell sorting of GFP positive OSCC cells.  
WHCO1 and WHCO6 OSCC cells previously infected with lentiviral particles containing Ctrl, IGF-1R or 
CXCR2 shRNA were cultured to 60-70% confluency. Cells were trypsinized, resuspended in 1 x PBS and 
transferred to FACS polystyrene tubes for cell sorting. Wild type WHCO1 cells were used as a GFP negative 
control to set the appropriate gates so that GFP negative cells were excluded. All GFP positive cells were sorted 
and used for further experiments.  
Histogram Statistics




File: Data.001 Log Data Uni ts: Linear Values
Sample ID: NEG CONTROL Patient ID: 
Acquisition Date: 29-Mar-11 Gate: G1
Gated Events: 8185 Total Events: 10000
X Parameter: FL1-H (Log)
Histogram Statistics




File: Data.007 Log Data Uni ts: Linear Values
Sample ID: WHCO6 CTRL SH P18 Patient ID: 
Acquisition Date: 29-Mar-11 Gate: G1
Gated Events: 7650 Total Events: 10000
X Parameter: FL1-H (Log)
Histogram Statistics




File: Data.010 Log Data Uni ts: Linear Values
Sample ID: WHCO6 CTRL SH P18 POST SORT Patient ID: 
Acquisition Date: 29-Mar-11 Gate: G1
Gated Events: 6946 Total Events: 10000



















Marker Even s % Gated
All 81 5 100.00
M1 8180 99.94
M2 5 0. 6
File: Data.001 Log Data Uni ts: Linear Values
Sample ID: NEG CONTROL Patient ID: 
Acquisition Date: 29-Mar-11 Gate: G1
Gated Events: 8185 Total Events: 10000
X Parameter: FL1-H (Log)
Histogram Statistics




File: Data.002 Log Data Uni ts: Linear Values
Sample ID: WHCO1 CXCR2 SH P15 1ST RND Patient ID: 
Acquisition Date: 29-Mar-11 Gate: G1
Gated Events: 7487 Total Events: 10000
X Parameter: FL1-H (Log)
Histogram Statistics




File: Data.003 Log Data Uni ts: Linear Values
Sample ID: WHCO6 CXCR2 SH P14 1ST RND Patient ID: 
Acquisition Date: 29-Mar-11 Gate: G1
Gat d Events: 8403 Tot l Events: 10000










File: Data.004 Log Data Uni ts: Linear Values
Sample ID: WHCO1 CXCR2 SH P4 2ND RND Patient ID: 
Acquisition Date: 29-Mar-11 Gate: G1
Gated Events: 7971 Total Events: 10000












File: Data.005 Log Data Uni ts: Linear Values
Sample ID: WHCO6 CXCR2 SH P4 2ND RND Patient ID: 
Acquisition Date: 29-Mar-11 Gate: G1
Gated Events: 8361 Total Events: 10000
X Parameter: FL1-H (Log)
M1 M2
Histogram Statistics




File: Data.008 Log Data Uni ts: Linear Values
Sample ID: WHCO1 CTRL SH P20 Patient ID: 
Acquisition Date: 29-Mar-11 Gate: G1
Gated Events: 7463 Total Events: 10000
X Parameter: FL1-H (Log)
Histogram Statistics




File: Data.009 Log Data Uni ts: Linear Values
Sample ID: WHCO1 CTRL SH P20 POST SORT Patient ID: 
Acquisition Date: 29-Mar-11 Gate: G1
Gated Events: 7320 Total Events: 10000
X Parameter: FL1-H (Log)M1
M2
a l :	  WHCO1	  IGF-­‐1R	  shRNA	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  positive	  OSCC	  cells	  
























5.12 Solutions:  
 
30% Acrylamide solution 
30 g Acrylamide  
0.8 g Bisacrylamide 
0.1 g SDS (Sodium dodecyle sulphate) 
 Make up to 100 ml with dH2O, store at 4oC 
 
10% Ammonium Persulfate (APS) 
Weigh out 100 mg APS and dissolve in 1 ml dH2O, store at 4oC ≤1 months 
 
DEPC-treated water 
Add diethylpyrocarbonate (DEPC) to a final concentration of 0.01% (v/v), stir, let stand 
overnight and autoclave.  
 
0.5M EDTA pH 8.0 
Dissolve 37.22 g Na2EDTA·2H2O in 140 ml dH2O, adjust pH to 8 with 10 N NaOH and 
make up to 200 ml with dH2O and autoclave. 
 
Freezing Solution for cells 
70% DMEM 
20% Foetal calf serum 















Dissolve 20.33 g MgCl2·6H2O in 80 ml dH2O, make up to 100 ml and autoclave. 
 
5M NaCl 
Dissolve 29.17 g NaCl in 80 ml dH2O, make up to 100 ml and autoclave.  
 
10 x PBS  
2 g KCl 
80 g NaCl 
2 g KH2PO4 
11.5 g Na2HPO4 
Dissolve in 700 ml dH2O, adjust pH to 7.4 with 1 N HCL or 1 N NaOH, make up to 1 L with 
dH2O and autoclave. 
 
Pepstatin A (1mg/ml) 





















Resolving Gel Buffer 
36.2 g Tris  
0.8 g SDS 
Dissolve in 150 ml dH2O, pH to 8.9 with 1 N HCL or 1 N NaOH and make up to 200 ml with 
dH2O. Store at 4oC 
 
Stacking Gel Buffer 
5.9 g Tris  
0.4 g SDS 
Dissolve in 70 ml dH2O, pH to 6.8 with 1 N HCL or 1 N NaOH and make up to 100 ml with 
dH2O. Store at 4oC 
 
10x Running Buffer 
30.2 g Tris  
144 g Glycine 
10 g SDS 
Make up to 1 L with dH2O 
 
1x Running Buffer 
100 ml of 10x running buffer  















10x Transfer Buffer 
144 g Glycine 
38 g Tris 
Make up to 1 L with dH2O 
 
1x Transfer 
100 ml 10x transfer buffer (in this order) 
700 ml dH2O 
200 ml methanol/isopropanol  
 
10x Tris Buffered Saline  
60.5 g Tris 
87.6 g NaCl 
Dissolve in 700 ml dH2O, pH to 7.5 with 1 N HCL or 1 N NaOH and make up to 1 L with 
dH2O.  
 
1x TBST  
100 ml 10x TBS  
900 ml dH2O  


















1.4 ml β-mercaptoethanol 
40 ml 10% SDS / 4 g SDS powder 
12.5 ml 1M Tris-Cl pH 6.7 
Make up to 200 ml with dH2O 
 
5x Loading Buffer: 
1.75 g Tris 
30 ml glycerine 
Make up to approximately 40 ml with dH2O pH to 6.8 with 1 N HCl 
Add 5 g SDS 
Make up to a final volume of 50 ml with dH2O 
 
5x loading dye 
Heat the loading buffer to allow for the SDS precipitate to dissolve.  
Mix 100 µl 5 x loading buffer, 50 µl β-Mercaptoethanol and 50 µl 0.025% Bromophenol 




















150 mM NaCl                 1.752 g 
1% Triton X 100            2 ml (from 100% stock)  
0.1% SDS                       0.2 g 
10 mM Tris pH 7.5          2 ml (from 1 M stock) 
1% Na deoxycholate       2 g 
Make up to 200 ml with dH2O, store at 4oC. 
 
RIPA + Phosphatase and Protease Inhibitors  
 Stock concentration Final concentration Volume 
RIPA   817 µl 
10x Protease Inhibitors  10x 1x 100 µl 
NaF 1 M 50 mM 50 µl 
Na3VO4 0.1 M 2 mM 20 µl 
Pepstatin A 5 mg/ml 40 µg/ml 8 µl 
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Figure A1:  Effect of EGF or IGF-1 ligand on EGFR, IGF-2R, AKT and ERK1/2 levels    
WHCO1 and WHCO6 cells were seeded in 60 mm dishes at a density of 3 x 105 cells per dish and stimulated 
with either 20 ng/ml EGF or 50 ng/ml IGF-1 for the indicated time periods. Protein was harvested and subjected 

















































































Figure A2:  Effect of EGF on pIGF-1R in OSCC cells   
WHCO6, WHCO5 and Kyse180 cells were seeded at 3 x 105 cells per 60 mm dish and stimulated with 20 ng/ml 
EGF ligand over the indicated time period. Protein was harvested and subjected to western blot analysis probing 




































































Figure A3:  Effect IGF-1 treatment on pEGFR and pERK1/2 in WHCO5 OSCC cells.   
3 x 105 WHCO5 cells in 60 mm dishes were stimulated with 50 ng/ml of IGF-1 for the indicated time periods. 
Protein was harvested and 40 µg of protein was subjected to western blot analysis using antibodies specific for 


















































































Figure A4:  Cell cycle profile of WHCO1 and WHCO6 cells treated with 1 µM AG1478   
WHCO1 and WHCO6 cells were plated at 3 x 105 cells per 60 mm dish and left overnight to settle. The 
following day cells were treated with 1 µM AG1478 and cultured for a further 48 hr. Cells were harvested, 








































































Figure A5:  Protein sizes    


































Figure A6:  Spectra Multicolor Broad Range Protein Ladder    
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